

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2016341400 B2**

(54) Title
Single-chain CD137-receptor agonist proteins

(51) International Patent Classification(s)
C12N 15/62 (2006.01) **C07K 14/705** (2006.01)

(21) Application No: **2016341400** (22) Date of Filing: **2016.10.24**

(87) WIPO No: **WO17/068183**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/245,838	2015.10.23	US

(43) Publication Date: **2017.04.27**

(44) Accepted Journal Date: **2021.04.08**

(71) Applicant(s)
Apogenix AG

(72) Inventor(s)
Gieffers, Christian;Hill, Oliver;Thiemann, Meinolf;Schnyder, Tim

(74) Agent / Attorney
FPA Patent Attorneys Pty Ltd, Level 43 101 Collins Street, Melbourne, VIC, 3000, AU

(56) Related Art
WO 2010010051 A1



- (51) **International Patent Classification:**
C12N 15/62 (2006.01) C07K 14/705 (2006.01)
- (21) **International Application Number:**
PCT/EP2016/075543
- (22) **International Filing Date:**
24 October 2016 (24.10.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/245,838 23 October 2015 (23.10.2015) US
- (71) **Applicant:** APOGENIX AG [DE/DE]; Im Neuenheimer Feld 584, 69120 Heidelberg (DE).
- (72) **Inventors:** GIEFFERS, Christian; Blütenweg 12, 69221 Dossenheim (DE). HILL, Oliver; Greiner Str. 40, 69239 Neckarsteinach (DE). THIEMANN, Meinolf; Melissenweg 18, 69198 Schriesheim (DE). SCHNYDER, Tim; Tauberweg 2, 97999 Igersheim (DE).
- (74) **Agents:** WEICKMANN & WEICKMANN PARTMBB et al.; Postfach 860 820, 81635 München (DE).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS




Figure 1

(57) **Abstract:** Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fc fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS

Field of the Invention

5 The present invention provides specific CD137 receptor agonist proteins comprising three soluble CD137L domains and an Fc fragment, nucleic acid molecules encoding the CD137 receptor agonist proteins, and uses thereof. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

10

Background of the Invention

It is known that trimerization of TNF superfamily (TNFSF) cytokines is required for efficient receptor binding and activation. Trimeric complexes of TNF superfamily
15 cytokines, however, are difficult to prepare from recombinant monomeric units.

WO 01/49866 and WO 02/09055 disclose recombinant fusion proteins comprising a TNF cytokine and a multimerization component, particularly a protein from the C1q protein family or a collectin. A disadvantage of these fusion proteins is, however, that
20 the trimerization domain usually has a large molecular weight and/or that the trimerization is rather inefficient.

Schneider et al. (J Exp Med 187 (1989), 1205-1213) describe that trimers of TNF cytokines are stabilized by N-terminally positioned stabilization motifs. In CD95L, the
25 stabilization of the receptor binding domain trimer is presumably caused by N-terminal amino acid domains which are located near the cytoplasmic membrane.

Shiraishi et al. (Biochem Biophys Res Commun 322 (2004), 197-202) describe that the receptor binding domain of CD95L may be stabilized by N-terminally positioned artificial

α -helical coiled-coil (leucine zipper) motifs. It was found, however, that the orientation of the polypeptide chains to each other, e.g. parallel or antiparallel orientation, can hardly be predicted. Further, the optimal number of heptad-repeats in the coiled-coil zipper motif are difficult to determine. In addition, coiled-coil structures have the tendency to
5 form macromolecular aggregates after alteration of pH and/or ionic strength.

WO 01/25277 relates to single-chain oligomeric polypeptides which bind to an extracellular ligand binding domain of a cellular receptor, wherein the polypeptide comprises at least three receptor binding sites of which at least one is capable of
10 binding to a ligand binding domain of the cellular receptor and at least one is incapable of effectively binding to a ligand binding domain of the cellular receptor, whereby the single-chain oligomeric polypeptides are capable of binding to the receptor, but incapable of activating the receptor. For example, the monomers are derived from cytokine ligands of the TNF family, particularly from TNF- α .

15 WO 2005/103077 discloses single-chain fusion polypeptides comprising at least three monomers of a TNF family ligand member and at least two peptide linkers that link the monomers of the TNF ligand family members to one another. Recent experiments, however, have shown that these single-chain fusion polypeptides show undesired
20 aggregation.

WO 2010/010051 discloses single-chain fusion polypeptides comprising three soluble TNF family cytokine domains and at least two peptide linkers. The described fusion polypeptides are substantially non-aggregating.

25 Recent studies have shown that the *in vivo* anti tumor activity of an anti-CD137-mAb is dependent on Fc-gamma-R driven mechanisms and does not rely on agonistic activity only.

There is a need in the art for novel CD137 receptor agonists that exhibit high biological activity independent of Fc-gamma-R based crosslinking in vivo, high stability, and allow for efficient recombinant manufacturing.

5 Summary of the Invention

The present invention provides specific CD137 receptor agonist proteins that mimic the CD137:CD137L interaction in vivo, exhibit low proteolytic degradation and a shorter in vivo half-life as compared to agonistic monoclonal antibodies.

10

The CD137 receptor agonist proteins of the instant invention generally comprise: (i) a first soluble CD137L cytokine domain; (ii) a first peptide linker; (iii) a second soluble CD137L domain; (iv) a second peptide linker; (v) a third soluble CD137L domain; (vi) a third peptide linker (e.g., a hinge-linker) and (vii) an antibody Fc fragment.

15

In one embodiment, the antibody Fc fragment (vii) is located N terminal to the first CD137L domain (i) and/or C-terminal to the third CD137L domain (v). In another embodiment the antibody Fc fragment is located C-terminally to the third CD137L domain (v). In one embodiment, the polypeptide is substantially non-aggregating. In another embodiment, the second and/or third soluble CD137L domain is an N-terminally shortened domain which optionally comprises amino acid sequence mutations. In another embodiment, the soluble CD137L domains (i), (ii) and (iii) are an C-terminally shortened domain which optionally comprises amino acid sequence mutations.

20

25 In one embodiment, at least one of the soluble CD137L domains, particularly at least one of the soluble CD137L domains (iii) and (v), is a soluble CD137L domain with an N-terminal sequence which starts at amino acid D86 or R88 or Q89 or G90 of human CD137L and wherein D86 or R88 or Q89 may be replaced by a neutral amino acid, e.g., Ser or Gly. In another embodiment, at least one of the soluble CD137L domains, particularly at least one of the soluble CD137L domains (iii) and (v), is a soluble

30

CD137L domain with an N-terminal sequences selected from (a) D86– G90 and (b) (Gly/Ser)89 – G90. In one embodiment, the soluble CD137L domain ends with amino acid E254 of human CD137L and/or optionally comprises one or more mutation at positions D86, L87, R88, Q89, D112, V118, A154, A174, A176, A188, T241. In one
5 embodiment, the soluble CD137L domains (i), (iii) and (v) comprise amino acids D86 – E254 of human CD137L according to SEQ ID NO: 1.

In one embodiment, at least one of the soluble CD137L domains, particularly at least the soluble CD137L domains (i), is a soluble CD137L domain with an N-terminal sequence which starts at amino acid R88 and wherein R88 may be replaced by Ser or
10 Gly. In one embodiment, at least one of the soluble CD137L domains, particularly at least the soluble CD137L domain (iii), is a soluble C-terminal shortened CD137L domain ending with V240. In another embodiment, at least one of the soluble CD137L domains, particularly at least the soluble CD137L domains (iii), is a soluble C-terminal shortened CD137L domain ending with T241. In still another embodiment, at least one

15 of the soluble CD137L domains, particularly at least the soluble CD137L domains (iii), is a soluble C-terminal shortened CD137L domain ending with E243.

In one embodiment, the first and second peptide linkers (ii) and (iv) independently have a length of 3-8 amino acids, particularly a length of 3, 4, 5, 6, 7, or 8 amino acids, and preferably are glycine/serine linkers, optionally comprising an asparagine residue which
20 may be glycosylated. In one embodiment, the first and the second peptide linkers (ii) and (iv) consist of the amino acid sequence according to SEQ ID NO: 2. In another embodiment, the polypeptide additionally comprises an N-terminal signal peptide domain, *e.g.*, of SEQ ID NO: 17, which may comprise a protease cleavage site, and/or which additionally comprises a C-terminal element which may comprise and/or connect
25 to a recognition/purification domain, *e.g.*, a Strep-tag attached to a serine linker according to SEQ ID NO: 18.

In one embodiment, the antibody Fc fragment (vii) is fused to the soluble CD137L domain (i) and/or (v) via a hinge-linker, preferably of SEQ ID NO: 16. In another embodiment, the antibody Fc fragment (vii) consists of the amino acid sequence as
30 shown in SEQ ID NO: 13 or 14.

In one embodiment, the single-chain fusion polypeptide of the present invention comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 15, and 25-35.

In one embodiment, the present invention provides a CD137 receptor agonist protein comprising a dimer of two single-chain fusion polypeptides each having the amino acid sequence set forth in SEQ ID NO: 27. In one embodiment, the two polypeptides are covalently linked through three interchain disulfide bonds formed between cysteine residues 484, 490, and 493 of each polypeptide. Similar cysteine residues are positions 484, 490 and 493 of SEQ ID NO: 28, 29 or 32, positions 489, 495 and 498 of SEQ ID NO: 30, positions 493, 499 and 502 of SEQ ID NO: 31, and positions 487, 493 and 496 of SEQ ID NO: 33 or 34

In one embodiment, one or more of the asparagine residues at positions 158 and 318 of the mature polypeptide(s) SEQ ID NO: 27, 28 or 29 are N-glycosylated. In another embodiment, the asparagine residues at positions 158 and 318 of the polypeptide(s) are both N-glycosylated. Similar asparagine residues are positions 161 and 324 of SEQ ID NO: 30 or 31, and positions 159 and 320 of SEQ ID NO: 33 or 34

In another embodiment, the polypeptide(s) are further post-translationally modified. In another embodiment, the post-translational modification comprises the N-terminal glutamine of the D86Q mutein of the first soluble domain (i) modified to pyroglutamate.

In still another embodiment, the post-translational modification comprises the N-terminal glutamine of the first soluble domain (i) starting with Q89 modified to pyroglutamate.

Description of the Figures

Figure 1 Domain structure of a single-chain fusion polypeptide comprising three CD137L domains. I., II., III. Soluble CD137L domains.

Figure 2 Schematic picture representing the general structure of CD137L.

- ■ ■ Cell membrane, N-terminus located within the cell,
- 1. anti-parallel β -fold of receptor-binding domain (RBD),

2. interface of RBD and cell membrane,
3. protease cleavage site.

Figure 3 Single-chain fusion polypeptide comprising an additional Fab antibody
5 fragment.

Figure 4 Dimerization of two C-terminally fused single-chain Fc fusion polypeptides
via three disulfide bridges.

Figure 5 Schematic representation of the hexavalent single chain CD27 receptor
agonist fusion protein of the invention. CH2-Carbohydrates (5) present on
10 the inner surface areas normally shield the CH2-subdomain sterically (2)
from proteases during "open Fc-conformation transits" wherein hinge-
interchain disulfide bonds (4) are reduced and the covalent interchain
linkage is disrupted. This enables CH2-dissociation and exposure of the
inner surface areas and the upper hinge lysine K223 (6) towards
15 proteases. Dimer association in the "open stage" remains intact due to the
high affinity of the CH3 domains (3) to each other.

(1) scCD27L-RBD; (2) CH2 domain; (3) CH3 domain; (4) Hinge-Cysteines
(left side: oxidized to disulfide bridges; right side reduced stage with free
thiols); (5) CH2-Carbohydrates attached to N297 position (EU-numbering);
20 (6) Upper Hinge Lysine (K223)

Figure 6 ELISA assessing the binding of CD137 receptor agonist protein (Protein A)
to its receptor

Figure 7 Analytical size exclusion chromatography of strep tagged Protein A (SEQ
ID NO: 28) performed on a 1260 Infinity HPLC system using a Tosoh
25 TSKgelG3000SWxl column. The column was loaded with protein at a
concentration of 1 mg/ml in a total volume of 20 µl. The flow rate was set
to 0.5 ml/min. One observes a single main peak at 16.97 min for Protein A.
The low molecular weight buffer components of the sample elute after one
column volume (>23.5 min).

Figure 8 SDS-PAGE results of Protein A under non-reducing and reducing conditions.
360ng of Protein A were loaded on an SDS-PAGE 4-12% Bis-Tris gel under non-

reducing (Lane 1) or reducing (Lane 2) conditions containing DTT as reducing agent. Gels were run at 130V for 15 min followed by 180V for 60min and were subsequently stained using a silver-stain protocol. One observes a molecular weight difference between the main bands in A and B of about 70-80 kDa. As this is about half the molecular weight as observed for the main band in lane 1, this indicates that the homodimer in lane 2 is covalently linked by disulfide bridges. The bonds are lost under reducing conditions in lane 2

Detailed Description of the Invention

The present invention provides a single-chain fusion polypeptide comprising at least three soluble CD137L domains connected by two peptide linkers and N-terminally and/or C-terminally an antibody-derived dimerization domain. The inventors have discovered that dimerization of the two single-chain fusion polypeptides through the dimerization domain results in a hexavalent CD137 receptor agonist, which provides high biological activity and good stability.

Preferably, the single-chain fusion polypeptide is non-aggregating. The term "non-aggregating" refers to a monomer content of the preparation of $\geq 50\%$, preferably $\geq 70\%$ and more preferably $\geq 90\%$. The ratio of monomer content to aggregate content may be determined by examining the amount of aggregate formation using size-exclusion chromatography (SEC). The stability concerning aggregation may be determined by SEC after defined time periods, e.g. from a few to several days, to weeks and months under different storage conditions, e.g. at 4°C or 25°C . For the fusion protein, in order to be classified as substantially non-aggregating, it is preferred that the "monomer" content is as defined above after a time period of several days, e.g. 10 days, more preferably after several weeks, e.g. 2, 3 or 4 weeks, and most preferably after several months, e.g. 2 or 3 months of storage at 4°C , or 25°C . With regard to the definition of "monomer" in

the case of FC-fusion proteins, the assembly of two polypeptide chains is driven by the FC-part and the functional unit of the resulting assembled protein consists of two chains. This unit is defined as "monomer" in the case of Fc-fusion proteins regardless of being a dimerized single-chain fusion polypeptide.

5

The single-chain fusion polypeptide may comprise additional domains which may be located at the N- and/or C-termini thereof. Examples for additional fusion domains are e.g. an N-terminal signal peptide domain which may comprise a protease cleave site or a C-terminal element which may comprise and/or connect to a recognition/purification domain. According to a preferred embodiment, the fusion polypeptide comprises a Strep-tag at its C-terminus that is fused via a linker. An exemplary Strep-tag including a short serine linker is shown in SEQ ID NO: 18.

10

The CD137 receptor agonist protein of the present invention comprises three soluble domains derived from CD137L. Preferably, those soluble domains are derived from a mammalian, particularly human CD137L including allelic variants and/or derivatives thereof. The soluble domains comprise the extracellular portion of CD137L including the receptor binding domain without membrane located domains. Like other proteins of the TNF superfamily, CD137L is anchored to the membrane via an N-terminal portion of 15-30 amino acids, the so-called stalk-region. The stalk region contributes to trimerization and provides a certain distance to the cell membrane. However, the stalk region is not part of the trimeric receptor binding domain (RBD) with the receptor binding sites located at the protomer interfaces.

15

20

Importantly, the RBD of the Tumor Necrosis Factor Superfamily is characterized by a particular localization of its N- and C-terminal amino acids. Said amino acids are immediately adjacent and are located in close proximity to the axis of the trimer. The first N-terminal amino acids of the RBD form an anti-parallel beta-strand with a C-terminal region of the RBD. Thus, the aforementioned anti-parallel beta-strand of the RBD forms an interface with the cell membrane, which is connected to and anchored within the cell membrane via the amino acids of the stalk region.

25

30

Human CD137L contains a stalk region as well as most likely a C-terminal extension (V240-E254).

It is highly preferred that the soluble CD137L domains of the CD137 receptor agonist protein comprise a receptor binding domain of the CD137L lacking any amino acids from the stalk region. Otherwise, a long linker connecting the C-terminus of one of the soluble domains with the N -terminus of the next soluble domain would be required to compensate for the N-terminal stalk-region of the next soluble domain, which might result in instability and/or formation of aggregates. For the same reason, it is also highly preferred that the soluble CD137L domains of the CD137 receptor agonist protein comprise a receptor binding domain of the CD137L lacking any amino acids from the C-terminal extension.

A further advantage of such soluble domains is that the N-terminal amino acids of the RBD are not accessible for any anti-drug antibodies. Preferably, the single-chain fusion polypeptide consisting of (i) a first soluble CD137L domain; (ii) a first peptide linker; (iii) a second soluble CD137L domain; (iv) a second peptide linker; (v) a third soluble CD137L domain is capable of forming an ordered structure mimicking the trimeric organization of its natural counterpart thereby comprising at least one functional binding site for the respective CD137L receptor. The single-chain fusion polypeptide comprising components (i)-(v) is therefore also termed single-chain-CD137L-receptor-binding-domain (scCD137L-RBD). Importantly, compared to homotrimeric wild type CD137L-RBD, the scCD137L-RBD comprises an enhanced stability as the soluble CD137L domains (i), (iii) and (v) are enforced to trimerize by the covalent linkage to each other provided by the linkers (ii) and (iv).

The CD137 receptor agonist protein comprises three functional CD137 receptor binding sites, *i.e.* amino acid sequences capable of forming a complex with a CD137 receptor . Thus, the soluble domains are capable of binding to the corresponding CD137 receptor. In one embodiment, at least one of the soluble domains is capable of receptor activation, whereby apoptotic and/or proliferative activity may be affected. In a further

embodiment, one or more of the soluble domains are selected as not being capable of receptor activation.

The soluble CD137L domain may be derived from human CD137L as shown in SEQ ID

- 5 NO: 1. Preferably, the soluble CD137L domains are derived from human CD137L , particularly starting from amino acids 86, 88, 89 or 90 and comprise particularly amino acids 86-254 or 88-254 or 89-254 of SEQ ID NO: 1. Optionally, amino acid R88 of SEQ ID NO: 1 may be replaced by a non-charged amino acid, e.g. Ser or Gly or is replaced by Glutamine.

10 **Table 1: Sequence of Wild-Type Human CD137L Protein**

SEQ ID NO	Sequence
1	MEYASDASLDPEAPWPPAPRARACRVLPWALVAGLLLLLLLLAAACAVFLA CPWAVSGARASPGSAASPRREGPELSPDDPAGLLDLRQGMFAQLVAQNV LLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQ GRLHLHSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPS PRSE

As indicated above, the soluble CD137L domains may comprise the wild-type sequences as indicated in SEQ ID NO: 1. It should be noted, however, that it is possible
15 to introduce mutations in one or more of these soluble domains, e.g. mutations which alter (e.g. increase or decrease) the binding properties of the soluble domains. In one embodiment, soluble domains that cannot bind to the corresponding cytokine receptor can be selected.

- 20 In a further embodiment of the invention, the soluble CD137L domain (i) comprises a mutant of CD137L or a receptor binding domain thereof resulting in reduced affinity and/or reduced activation of CD137 receptor.

CD137L-Muteins affecting receptor binding and/or activity

The mutant may be generated by any technique known by a skilled person. The substitution may affect at least one amino acid of CD137L, *e.g.*, human CD137L (*e.g.*, SEQ ID NO: 1) or a receptor binding domain thereof as described herein. Preferred

5 substitutions in this regard affect at least one of the following amino acids of human CD137L of SEQ ID NO: 1: L115, K127, R150, R193 and Q227.

In another preferred embodiment, the C-terminal region I243-E254 is deleted from at least one of the soluble domains (i), (III) or (v).

The amino acid substitution(s) may affect the binding and/or activity of CD137L, *e.g.*,

10 human CD137L, to or on either the CD137 binding or the CD137 induced signaling.

The binding and/or activity of the CD137 may be affected positively, *i.e.*, stronger, more selective or more specific binding and/or more activation of the receptor. Alternatively, the binding and/or activity of the CD137 may be affected negatively, *i.e.*, weaker, less selective or less specific binding and/or less or no activation of the receptor.

15 Thus one embodiment is a CD137 receptor agonist protein as described herein wherein at least one of the soluble domains comprises a mutant of CD137L or a receptor binding domain thereof which binds and/or activates CD137 to a lesser extent than the wildtype-CD137L.

CD137L-Muteins with enhanced stability/solubility

20 In a further embodiment of the invention, one or more of the soluble CD137L domains (i), (iii), and (v) may comprise a mutant of CD137L or a receptor binding domain thereof resulting in reduced self-aggregation and/or prolonged in vivo stability. A174, A176. Preferred substitutions in this regard are A174[D, N] and A176[S, T]. The mutation(s) of each CD137L domain may be the same or different.

25 The single-chain fusion molecule of the present invention comprises three soluble CD137L domains, namely components (i), (iii) and (v). The stability of a single-chain CD137L fusion polypeptide against aggregation is enhanced, if the second and/or third soluble CD137L domain is an N-terminally shortened domain which optionally comprises amino acid sequence mutations. Thus, preferably, both the second and the

30 third soluble CD137L domain are N-terminally shortened domains which optionally

comprise amino acid sequence mutations in the N-terminal regions, preferably within the first five amino acids of the N-terminus of the soluble CD137L domain. These mutations may comprise replacement of basic amino acids, by neutral amino acids, particularly serine or glycine.

5

In contrast thereto, the selection of the first soluble CD137L domain is not as critical. Here, a soluble domain having a full-length N-terminal sequence may be used. It should be noted, however, that also the first soluble CD137L domain may have an N-terminally shortened and optionally mutated sequence.

10

In a further preferred embodiment of the present invention, the soluble CD137L domains (i), (iii) and (v) are soluble human CD137L domains. The first soluble CD137L domain (i) may be selected from native, shortened and/or mutated sequences. Thus, the first soluble CD137L domain (i) has an N-terminal sequence which may start at amino acid D86 or R88 of human CD137L, and wherein R88 may be replaced by a neutral amino acid, *e.g.* by Ser or Gly or by Gln to enable pyroglutamate formation during expression. The second and third soluble CD137L domains (iii) and (v) have a shortened N-terminal sequence which preferably starts with amino acid Q89 or G90 of human CD137L (SEQ ID NO:1) and wherein Q89 may be replaced by another amino acid, *e.g.* Ser or Gly.

15

20

Preferably, the N-terminal sequence of the soluble CD137L domains (iii) and (v) is selected from:

(a) D86 or Q89

25

(b) (Gly/Ser) 89

The soluble CD137L domain preferably ends with amino acid E254 of human CD137L. In certain embodiments, the CD137L domain may comprise internal mutations as described above.

30

In another preferred embodiment, the soluble CD137L domain preferably ends with amino acid V240 of human CD137L. In certain embodiments, the CD137L domain may comprise internal mutations as described above.

- 5 Components (ii) and (iv) of the CD137 receptor agonist protein are peptide linker elements located between components (i) and (iii) or (iii) and (v), respectively. The flexible linker elements have a length of 3-8 amino acids, particularly a length of 3, 4, 5, 6, 7, or 8 amino acids. The linker elements are preferably glycine/serine linkers, *i.e.* peptide linkers substantially consisting of the amino acids glycine and serine. In cases
10 in in which the soluble cytokine domain starts with S or G (N-terminus), the linker ends before this S or G.

- It should be noted that linker (ii) and linker (iv) do not need to be of the same length. In order to decrease potential immunogenicity, it may be preferred to use shorter linkers.
15 In addition it turned out that shorter linkers lead to single chain molecules with reduced tendency to form aggregates. Whereas linkers that are substantially longer than the ones disclosed here may exhibit unfavorable aggregations properties.

- If desired, the linker may comprise an asparagine residue which may form a glycosylate
20 site Asn-Xaa-Ser. In certain embodiments, one of the linkers, *e.g.* linker (ii) or linker (iv) comprises a glycosylation site. In other embodiments, both linkers (iv) comprise glycosylation sites. In order to increase the solubility of the CD137L agonist proteins and/or in order to reduce the potential immunogenicity, it may be preferred that linker (ii) or linker (iv) or both comprise a glycosylation site.

25

Preferred linker sequences are shown in Table 2. A preferred linker is GSGSGNGS (SEQ ID NO: 2).

Table 2: Example Linker Sequences

SEQ ID NO	Sequence
2	GSGSGNGS

3	GSGSGSGS
4	GGSGSGSG
5	GGSGSG
6	GGSG
7	GGSGNGSG
8	GGNGSGSG
9	GGNGSG
10	GSGSGS
11	GSGS
12	GSG

The CD137 receptor agonist protein additionally comprises an antibody Fc fragment domain which may be located N-terminal to the first CD137L domain (i) and/or C-terminal to the third CD137L domain (v). Preferably, the antibody Fc fragment domain comprises a reduced capability to interact with Fc-gamma-R receptors in vivo.

Preferably, the antibody Fc fragment domain comprises or consists of an amino acid sequence as shown in SEQ ID NO: 13 or 14 (see Table 3). Sequence ID NO: 13 has N297S mutation compared to wildtype human IGG1-Fc. Sequence ID NO: 14 is a

glycosylated (N297 wildtype) human IGG1 Fc mutein with reduced Fc-gamma-R binding capability.

Table 3: Examples of Fc Fragment Domains

SEQ ID NO	Sequence
13	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYSSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDS DGSFFLYSKLTVDKSRWQQGNV FSCSV MHEALH NHYTQKSLSLSPGK
14	PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI

	EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK
--	---

Number of glycosylation sites and in vivo stability

The total number of glycosylation sites and the individual position of the carbohydrates in three dimensions impacts the in-vivo stability of CD137 receptor agonist proteins.

Further, carbohydrate recognition depends on local density of the terminal saccharides, the branching of the carbohydrate tree and the relative position of the carbohydrates to each other matter.

Further, partially degraded carbohydrates reduce the *in vivo* half-life of CD137 receptor agonist proteins through lectin-driven mechanisms. By reducing the total number of glycosylation sites on the molecule, the resulting compound is less accessible to these mechanisms, increasing half-life.

Depletion of the CH2-domain carbohydrates of the Fc-domain is necessary in order to avoid Fc-gamma-Receptor based binding. FcR-gamma-Receptors on cells could lead to hyper-crosslinking of the fusion-protein *in vivo* potential leading to CD137-receptor superclustering-based toxicity. Also, unwanted Fc-driven mechanisms like ADCC could lead to toxic events. Accordingly, in one embodiment, the overall number of glycosylation sites on the CD137 receptor agonist proteins of the instant invention is reduced through the depletion of CH2 glycosylation sites, particularly the N-glycosylation site, resulting in CD137 receptor agonist proteins comprising N297S equivalent mutations of SEQ ID NO: 15 (PROTEIN A) (according to the EU numbering system) creating aglycosyl-CH2 domains.

CH2-domain destabilization is compensated by an additional hinge-cysteine

CH2-glycosylation present on the inner surface areas normally shields the subdomain from proteases during "open Fc-conformation transits" wherein hinge-interchain disulfide bonds are reduced and the covalent interchain linkage is disrupted. This enables CH2-dissociation and exposure of the inner surface area towards proteases.

CD137 receptor agonist proteins comprising an Fc-domain with a N297S equivalent mutation of SEQ ID NO: 15 (PROTEIN A) (according to the EU numbering system) creates an aglycosylated-CH2 and are therefore likely to be subject to protease digestion and less stable than equivalent structures with wild-type CH2 glycosylation.

5 This would impact the compound's stability during USP/DSP/storage, where host cell proteases are present and have long-term access to the structure. Accordingly, in certain embodiments, the CD137 receptor agonist lacks CH2 glycosylation sites, but comprises glycosylation sites in the linker sequences of each polypeptide chain (e.g., GSGSGNGS, SEQ ID NO: 2).

10 According to a preferred embodiment of the invention, the antibody Fc fragment domain is fused via a hinge-linker element. The hinge-linker element has a length of 10-30 amino acids, particularly a length of 15-25 amino acids, e.g. 22 amino acids. The term "hinge-linker" includes any linker long enough to allow the domains attached by the hinge-linker element to attain a biologically active conformation. The hinge-linker
15 element preferably comprises the hinge-region sequence of an immunoglobulin, herein referred to as "Ig hinge-region". The term "Ig hinge-region" means any polypeptide comprising an amino acid sequence that shares sequence identity or similarity with a portion of a naturally occurring Ig hinge-region sequence which includes one or more cysteine residues, e.g., two cysteine residues, at which the disulfide bonds link the two
20 heavy chains of the immunoglobulin.

Derivatives and analogues of the hinge-region can be obtained by mutations. A derivative or analogue as referred to herein is a polypeptide comprising an amino acid sequence that shares sequence identity or similarity with the full length sequence of the
25 wild type (or naturally occurring protein) except that it has one or more amino acid sequence differences attributable to a deletion, insertion and/or substitution.

The number of molecules with open Fc-conformation in an individual CD137 receptor agonist protein depends on the number of interchain-disulfide bonds present in the
30 hinge region. Accordingly, in one embodiment a third cysteine (C225 according to the EU numbering system) was introduced into the hinge region of the CD137 receptor

agonist proteins of the instant invention in order to ameliorate the effect of depleting the CH2-glycosites.

Exchange of a lysine to glycine in the hinge region results in enhanced proteolytic stability

5 In one embodiment, the CD137 receptor agonist proteins of the invention additionally comprise a mutation of the upper-hinge lysine (K223, according to the EU numbering system) to a glycine to reduce proteolytic processing at this site, thereby enhancing the overall stability of the fusion protein. Combining aforementioned introduction of a third
10 cysteine (C225, according to the EU numbering system) with the aforementioned lysine to glycine mutation (K223G, according to the EU numbering system) within the hinge region results in an overall stabilized CD137 receptor agonist protein of the instant invention.

A particularly preferred hinge-linker element including the aforementioned cysteine (C225) and the lysine to glycine mutation (K223G) comprises or consists of the amino
15 acid sequence as shown in SEQ ID NO: 16 (Table 4).

The CD137 receptor agonist protein may additionally comprise an N-terminal signal peptide domain, which allows processing, *e.g.* extracellular secretion, in a suitable host cell. Preferably, the N-terminal signal peptide domain comprises a protease cleavage
20 site, *e.g.* a signal peptidase cleavage site and thus may be removed after or during expression to obtain the mature protein. A particularly preferred N-terminal signal peptide domain comprises the amino acid sequence as shown in SEQ ID NO: 17 (Table 4).

25 Further, the CD137 receptor agonist protein may additionally comprise a C-terminal element, having a length of *e.g.* 1-50, preferably 10-30 amino acids which may include or connect to a recognition/purification domain, *e.g.* a FLAG domain, a Strep-tag or Strep-tag II domain and/or a poly-His domain. According to a preferred embodiment, the fusion polypeptide comprises a Strep-tag fused to the C-terminus via a short serine
30 linker as shown in SEQ ID NO: 18 (Table 4).

Preferred hinge-linker elements (SEQ ID NO: 16, 19-24), a preferred N-terminal signal peptide domain (SEQ ID NO: 17) and a preferred serine linker-strep tag (SEQ ID NO: 18) are shown in Table 4.

5 **Table 4: Exemplary domains and linkers**

SEQ ID NO	Sequence
16	GSSSSSSSSGSCDKTHTCPPC
17	METDTLLVFVLLVWVPAGNG
18	SSSSSSAWSHHPQFEK
19	GSSSSSSSSGSCDKTHTCPPC
20	GSSSSSSGSCDKTHTCPPC
21	GSSSSSGSCDKTHTCPPC
22	GSSSGSCDKTHTCPPC
23	GSSSGSCDKTHTCPPCGS
24	GSSSGSCDKTHTCPPCGSGS

In one embodiment of the invention, the fusion polypeptide comprises three soluble CD137L domains fused by peptide linker elements of SEQ ID NO: 2. All three soluble CD137L domain (i), (iii), (v) consists of amino acids 89-240 of human CD137L

10 according to SEQ ID NO: 1. The resulting scCD137L-RBD sequence module is shown in table 5b SEQ ID NO: 36.

In a further preferred embodiment of the invention, the fusion polypeptide comprises three soluble CD137L domains fused by peptide linker elements of SEQ ID NO: 2. All
 15 three soluble CD137L domain (i), (iii), (v) consists of amino acids 86-240 of human CD137L according to SEQ ID NO: 1 with D86Q mutation in the first domain (i). The resulting scCD137L-RBD sequence module is shown in table 5b SEQ ID NO: 39.

In another embodiment of the invention, the fusion polypeptide comprises three soluble CD137L domains fused by peptide linker elements of SEQ ID NO: 2. All three soluble CD137L domain (i), (iii), (v) consists of amino acids 88-240 of human CD137L according to SEQ ID NO: 1. The resulting scCD137L-RBD sequence module is shown in table 5b SEQ ID NO: 40.

In still another preferred embodiment of the invention, the fusion polypeptide comprises three soluble CD137L domains fused by peptide linker elements of SEQ ID NO: 2. All three soluble CD137L domain (i), (iii), (v) consists of amino acids 88-240 of human CD137L according to SEQ ID NO: 1 with R88Q mutation in the first domain (i) and R88G mutation in domains (iii) and (v). The resulting scCD137L-RBD sequence module is shown in table 5b SEQ ID NO: 41.

In still another preferred embodiment of the invention, the fusion polypeptide comprises three soluble CD137L domains fused by peptide linker elements of SEQ ID NO: 2. All three soluble CD137L domain (i), (iii), (v) consists of amino acids 88-240 of human CD137L according to SEQ ID NO: 1 with R88S mutation in the first domain (i) and R88G mutation in domains (iii) and (v). The resulting scCD137L-RBD sequence module is shown in table 5b SEQ ID NO: 42.

In still another preferred embodiment of the invention, the fusion polypeptide comprises three soluble CD137L domains fused by peptide linker elements of SEQ ID NO: 2. All three soluble CD137L domain (i), (iii), (v) consists of amino acids 89-240 of human CD137L according to SEQ ID NO: 1 and comprise the A174N and A176S mutations. The resulting scCD137L-RBD sequence module is shown in table 5b SEQ ID NO: 43.

The aforementioned scCD137L-RBD modules (SEQ ID: 36, 39-43) are well suited to generate fusion proteins with additional domains fused to either N-or C-terminal end employing the linkers described in Table 2 (SEQ ID NO: 2-12).

Preferred configuration CD137L-Fc

Additionally, the fusion polypeptide comprises an antibody Fc fragment domain according to SEQ ID NO: 13 that is fused C-terminally to the soluble CD137L domain (v) via a hinge-linker according to SEQ ID NO: 16. The inventors surprisingly found that this particular fusion polypeptide provides improved biological activity as compared to bivalent agonistic anti-CD137-mAB and has a prolonged stability as compared to fusion proteins comprising a lysine in position 223 and a N297S mutation in the CH2 domain (according to the EU numbering).

The amino acid sequence of an exemplary embodiment of a CD137 receptor agonist protein of the invention is set forth in SEQ ID NO: 27.

Further, the fusion polypeptide may comprise an N-terminal signal peptide domain *e.g.* according to SEQ ID NO: 17. A specific example of a CD137 receptor agonist protein of the invention is shown in SEQ ID NO: 25.

According to another preferred embodiment, the fusion polypeptide may additionally comprise a C-terminal Strep-tag that is fused to the polypeptide of the invention via a short serine linker as shown in SEQ ID NO: 18. According to this aspect of the invention, the Fc fragment preferably consists of the amino acid sequence as shown in SEQ ID NO: 13 or 14. Further, the Fc fragment may consist of a shorter Fc fragment, for example including amino acids 1-217 of SEQ ID NO: 13. Particularly preferred examples of fusion polypeptides comprising a C-terminal Strep-tag are shown in SEQ ID NO: 15 (PROTEIN A).

The exemplary CD137 receptor agonist proteins as shown in SEQ ID Nos: 15, 25, and 26, each comprises an N-terminal signal peptide domain, at amino acids 1-20 of each sequence. In each case, the mature protein starts with amino acid 21. Mature exemplary CD137 receptor agonist proteins (without a signal peptide) of the instant invention are set forth in SEQ ID NO: 27-35. Exemplary CD137 receptor agonist proteins described above are shown in Table 5.

The CD137 receptor agonist as set forth in SEQ ID NO: 27 has a reduced total number of glycosylation sites (the N297S mutation in the CH2 region providing an aglycosylated CH2 domain, according to the EU numbering system), an increased number of inter-chain disulfide bonds in the hinge region, and the mutation of an upper-hinge lysine to a glycine (K223G, according to the EU numbering system). These alterations provide a decrease in potential degradation and CD137 receptor superclustering (along with concomitant toxicity).

The CD137 receptor agonist as set forth in SEQ ID NO: 30 comprises a scCD137L-RBD module with SEQ ID NO: 36, a third peptide linker with SEQ ID NO: 21 and (vii) an antibody Fc fragment with SEQ ID NO: 13.

The CD137 receptor agonist as set forth in SEQ ID NO: 31 comprises a scCD137L-RBD module with SEQ ID NO: 39, a third peptide linker with SEQ ID NO: 16 and (vii) an antibody Fc fragment with SEQ ID NO: 13.

The CD137 receptor agonist as set forth in SEQ ID NO: 32 comprises a scCD137L-RBD module with SEQ ID NO: 40, a third peptide linker with SEQ ID NO: 16 and (vii) an antibody Fc fragment with SEQ ID NO: 13.

The CD137 receptor agonist as set forth in SEQ ID NO: 33 comprises a scCD137L-RBD module with SEQ ID NO: 41, a third peptide linker with SEQ ID NO: 16 and (vii) an antibody Fc fragment with SEQ ID NO: 13.

The CD137 receptor agonist as set forth in SEQ ID NO: 34 comprises a scCD137L-RBD module with SEQ ID NO: 42, a third peptide linker with SEQ ID NO: 16 and (vii) an antibody Fc fragment with SEQ ID NO: 13.

Table 5: Exemplary CD137 receptor agonist proteins

SEQ ID NO	Sequence
-----------	----------

25 PROTEIN A without StrepTag	METDTLLVFVLLVWVPAGNGQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLS YKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALT VDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFR VGSGSGNGSQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVA KAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQG MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLE ELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLL HLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSSSSSSSSGSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYSSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
15 PROTEIN A	METDTLLVFVLLVWVPAGNGQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLS YKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALT VDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFR VGSGSGNGSQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVA KAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQG MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLE ELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLL HLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSSSSSSSSGSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYSSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGSSSSSSSAWSHP QFEK
26 CD137L-wt +SEQ14	METDTLLVFVLLVWVPAGNGQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLS YKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALT VDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFR VGSGSGNGSQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVA KAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQG MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLE

	ELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLL HLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSSSSSSSSSGSCDKTHTCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVVFSCSVMEALHNHYTQKSLSLSPGK
27 CD137L-wt +SEQ13 FC No Signal No Strep No Glyco	QGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFF QLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGR LLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQGMFAQLVAQN VLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFFQLELRRVVAGE GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG VHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQGMFAQLVAQNVLIDGPLSWY SDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFFQLELRRVVAGEGSGSVSLALHL QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARH AWQLTQGATVLGLFRVGSSSSSSSSSGSCDKTHTCPPCPAPPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMEALHNHYTQKSLSLSPGK
28 Deglyco-Fc No Signal + StrepTag	QGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFF QLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGR LLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQGMFAQLVAQN VLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFFQLELRRVVAGE GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG VHLHTEARARHAWQLTQGATVLGLFRVGSGSGNGSQGMFAQLVAQNVLIDGPLSWY SDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFFQLELRRVVAGEGSGSVSLALHL QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARH AWQLTQGATVLGLFRVGSSSSSSSSSGSCDKTHTCPPCPAPPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMEALHNHYTQKSLSLSPGSSSSSSSAWSHPQFEK
29 Glyco FC	QGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVAKAGVYVFF QLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGR

No Signal No strep	LLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYYVFFQLELRRRVVAGE GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG VHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYYVFFQLELRRRVVAGE GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARH AWQLTQGATVLGLFRVSGSSSSSSSSGSCDKTHTCPPCPAPPVAGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCCLKVGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMEALHNHYTQKSLSLSPGK
30 SEQ39+FC 13 Linker 21	QLRQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYY VFFQLELRRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGS DLRQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYYVFFQLELR RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGS DLRQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYYVFFQLELRRRVVAGEGS GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVH LHTEARARHAWQLTQGATVLGLFRVSGSSSSGSCDKTHTCPPCPAPPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYR VVS VLT TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMEALHNHYTQKSLSLSPGK
31	QLRQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYY VFFQLELRRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGS DLRQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYYVFFQLELR RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGS DLRQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYYVFFQLELRRRVVAGEGS GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVH LHTEARARHAWQLTQGATVLGLFRVSGSSSSSSSSGSCDKTHTCPPCPAPPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYS

	STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
32	RQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVF FQLELRRVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSRQGMFAQLVA QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVFFQLELRRVVA GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR LGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSRQGMFAQLVAQNVLLIDGPL SWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVFFQLELRRVAGEGSGSVSLA LHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR ARHAWQLTQGATVLGLFRVGSSSSSSGSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCFSVMHEALHNHYTQKSLSLSPGK
33	QQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVF FQLELRRVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSGQGMFAQLVA QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVFFQLELRRVVA GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR LGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSGQGMFAQLVAQNVLLIDGPL SWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVFFQLELRRVAGEGSGSVSLA LHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR ARHAWQLTQGATVLGLFRVGSSSSSSSSGSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFCFSVMHEALHNHYTQKSLSLSPGK
34	SQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVF FQLELRRVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSGQGMFAQLVA QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAAGVYYVFFQLELRRVVA GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR

	LGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVAQNVLIDGPL SWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLA LHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR ARHAWQLTQGATVLGLFRVGSSSSSSSSSGSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
35 (Seq27 with additional glycol-sites)	QGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFF QLELRRVVAGEGSGSVSLALHLQPLRSANGSAALALTVDLPPASSEARNSAFGFQGR LLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE GSGSVSLALHLQPLRSANGSAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG VHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVAQNVLIDGPLSWY SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL QPLRSANGSAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARH AWQLTQGATVLGLFRVGSSSSSSSSSGSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

Table 5B: Exemplary scCD137L-RBD modules

36	QGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFF QLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGR LLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG VHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVAQNVLIDGPLSWY SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL
-----------	---

	QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARH AWQLTQGATVLGLFRV
39	QLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYY VFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSDLRQGMFA QLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSDLRQGMFAQLVAQNVL LIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGS GSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVH LHTEARARHAWQLTQGATVLGLFRV
40	RQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVF FQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSRQGMFAQLVA QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVA GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR LGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSRQGMFAQLVAQNVLLIDGPL SWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLA LHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR ARHAWQLTQGATVLGLFRV
41	QQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVF FQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVA QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVA GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR LGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVAQNVLLIDGPL SWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLA LHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR ARHAWQLTQGATVLGLFRV
42	SQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVF FQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVSGSGNGSgQGMFAQLVA QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVA GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR

	LGVHLHTEARARHAWQLTQGATVLGLFRVGS GSGNGSgQGMFAQLVAQNVLIDGPL SWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLA LHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR ARHAWQLTQGATVLGLFRV
43	QGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFF QLELRRVVAGEGSGSVSLALHLQPLRSANGSAALALTVDLPPASSEARNSAFGFQGR LLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVGS GSGNGSgQGMFAQLVAQN VLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE GSGSVSLALHLQPLRSANGSAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG VHLHTEARARHAWQLTQGATVLGLFRVGS GSGNGSgQGMFAQLVAQNVLIDGPLSWY SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL QPLRSANGSAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARH AWQLTQGATVLGLFRV

A further aspect of the present invention relates to a nucleic acid molecule encoding a
 CD137 receptor agonist protein as described herein. The nucleic acid molecule may be
 a DNA molecule, *e.g.* a double-stranded or single- stranded DNA molecule, or an RNA
 molecule. The nucleic acid molecule may encode the CD137 receptor agonist protein or
 a precursor thereof, *e.g.* a pro- or pre-proform of the CD137 receptor agonist protein
 which may comprise a signal sequence or other heterologous amino acid portions for
 secretion or purification which are preferably located at the N- and/or C-terminus of the
 CD137 receptor agonist protein. The heterologous amino acid portions may be linked to
 the first and/or second domain via a protease cleavage site, *e.g.* a Factor X3, thrombin
 or IgA protease cleavage site. A specific example of a nucleic acid sequence of the
 invention is shown in Table 6 as SEQ ID NO: 37. This nucleic acid molecule comprises
 the open reading frame encoding the fusion polypeptide of SEQ ID NO: 25.

Table 6: Nucleic Acid Sequence of Exemplary CD137 receptor agonist protein

SEQ ID NO	Sequence
-----------	----------

37	AAGCTTTAGGGATAACAGGGTAATAGCCGCCACCATGGAGACTGACACCCTGCT GGTGTTCGTGCTGCTGGTCTGGGTGCCTGCAGGAAATGGACAGGGCATGTTTCGC TCAACTGGTCGCACAGAACGTGCTGCTCATTGACGGTCCCCTGTCTTGGTACTC CGATCCAGGGTTGGCAGGAGTGTCTTGACAGGAGGGCTGTCTATAAGGAGGA TACCAAAGAGCTGGTGGTAGCAAAGGCTGGTGTGTATTACGTGTTCTTTCAGCT GGAGCTGCGCAGAGTCGTGCGAGGCGAAGGATCTGGTAGTGTGTCACTGGCACT GCACTTGACAGCCCCCTTCGGTCCGCTGCCGGGGCAGCAGCACTGGCCCTGACCGT CGATCTGCCACCCGCTTCTAGCGAGGCACGAACTCAGCCTTTGGGTTTCAGGG TCGCCTGCTGCACCTGAGCGCCGGACAGAGGCTGGGCGTTCATCTGCACACCGA GGCCAGAGCCAGACACGCTTGGCAGTTGACTCAGGGAGCTACGGTCCTCGGTCT GTTTCGAGTAGGCAGCGGAAGCGGCAATGGCTCTCAGGGCATGTTTGCTCAGCT GGTAGCCAGAACGTACTCCTGATCGATGGCCCTCTTTCATGGTACTCAGACCC CGGACTGGCCGGAGTTAGCCTTACAGGTGGGCTTAGTTATAAGGAGGACACAAA GGAATTGGTTGTGGCCAAAGCTGGCGTGTACTATGTGTTCTTCCAGCTTGAGCT CCGCAGAGTCGTGGCTGGGGAGGGCTCTGGCAGTGTGAGCCTTGCCCTTCATCT GCAACCTTTGCGGAGCGCAGCCGGCGCTGCTGCACTGGCCCTTACAGTGGATTT GCCACCCGCAAGTAGTGAAGCTCGCAATTCGCGATTCCGTTTCCAGGGCCGTCT GCTCCATCTTTCTGCCGGTCAACGTCTGGGAGTTCACCTCCACACTGAGGCTAG GGCCAGGCATGCTTGGCAGCTGACTCAAGGAGCCACTGTCTTGGGACTCTTTCG GGTAGGCTCCGGGTCTGGCAACGGCTCCCAGGGGATGTTTGCCCAACTGGTCGC CCAGAATGTCTGCTCATCGATGGTCCTCTGAGCTGGTATTCCGACCCTGGACT GGCTGGTGTGAGCCTGACTGGCGGACTCTCCTACAAAGAGGACACCAAGGAACT GGTGGTGGCCAAAGCCGGGGTGTACTACGTGTTCTTCCAGTTGGAAGTGC GGCG GGTTGTGGCTGGCGAGGGATCAGGTTCCGTTAGTCTGGCCCTGCACCTCCAGCC TCTGAGGTCTGCTGCTGGTGCCGCCGCTCTGGCCTTGACCGTCGACCTCCCACC CGCATCTTCCGAAGCCCGAAATTCAGCCTTCGGGTTCAGGGCAGACTGCTGCA TCTGAGTGCTGGACAGCGCCTTGGGGTTCATCTCCACACCGAAGCCAGGGCCCCG ACATGCCTGGCAGCTCACACAAGGCGCAACCGTTTTGGGGCTCTTTCGTGTGgg atcctcgagTTCATCGTCCTCATCCGGCTCATGTGATAAGACCCACACCTGCCC TCCCTGTCCTGCCCCCTGAGCTGCTGGGCGGACCTTCTGTGTTCTGTTCCCCC CAAGCCTAAGGACACCCTGATGATCTCCAGGACCCCTGAGGTGACCTGTGTGGT GGTGGACGTGTCTCACGAAGATCCCGAGGTGAAGTTCAACTGGTACGTGGACGG CGTGGAGGTCCACAACGCCAAGACCAAGCCTAGGGAGGAGCAGTACAGCTCCAC CTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGAAA
----	--

	GGAGTATAAGTGTAAGGTCTCCAACAAGGCCCTGCCTGCCCCATCGAGAAAAC CATCTCCAAGGCCAAGGGCCAGCCTCGGGAGCCTCAGGTGTACACCCTGCCTCC TAGCAGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGG CTTCTACCCCTCCGATATCGCCGTGGAGTGGGAGTCTAATGGCCAGCCCGAGAA CAACTACAAGACCACCCCTCCTGTGCTGGACTCTGACGGCTCCTTCTTCCTGTA CTCCAAGCTGACCGTGGACAAGTCCAGATGGCAGCAGGGCAACGTGTTCTCCTG CTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTCCCTGTCTCT GAGTCCGGGCAAGTAATAggcgcgcc
--	---

The nucleic acid molecule may be operatively linked to an expression control sequence, *e.g.* an expression control sequence which allows expression of the nucleic acid molecule in a desired host cell. The nucleic acid molecule may be located on a vector, *e.g.* a plasmid, a bacteriophage, a viral vector, a chromosomal integration vector, etc. Examples of suitable expression control sequences and vectors are described for example by Sambrook et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, and Ausubel et al. (1989), *Current Protocols in Molecular Biology*, John Wiley & Sons or more recent editions thereof.

Various expression vector/host cell systems may be used to express the nucleic acid sequences encoding the CD137 receptor agonist proteins of the present invention. Suitable host cells include, but are not limited to, prokaryotic cells such as bacteria, *e.g.* *E. coli*, eukaryotic host cells such as yeast cells, insect cells, plant cells or animal cells, preferably mammalian cells and, more preferably, human cells. Further, the invention relates to a non-human organism transformed or transfected with a nucleic acid molecule as described above. Such transgenic organisms may be generated by known methods of genetic transfer including homologous recombination.

A further aspect of the present invention relates to a pharmaceutical or diagnostic composition comprising as the active agent at least one CD137 receptor agonist protein, a respective nucleic acid encoding therefore, or a transformed or transfected cell, all as described herein.

In another aspect, the present invention provides a pharmaceutical composition comprising an CD137 receptor agonist protein disclosed herein and one or more pharmaceutically acceptable carriers, diluents, excipients, and/or adjuvants.

In another aspect, the present invention provides a nucleic acid molecule encoding the CD137 receptor agonist protein. In another embodiment, the present invention provides an expression vector comprising the nucleic acid molecule. In another embodiment, the present invention provides a cell comprising the nucleic acid molecule. In a further embodiment, the cell is a eukaryotic cell. In another embodiment, the cell is a mammalian cell. In another embodiment, the cell is a Chinese Hamster Ovary (CHO) cell. In other embodiments, the cell is selected from the group consisting of CHO-DBX11, CHO-DG44, CHO-S, and CHO-K1 cells. In other embodiments, the cell is selected from the group consisting of Vero, BHK, HeLa, COS, MDCK, HEK-293, NIH-3T3, W138, BT483, Hs578T, HTB2, BT20, T47D, NS0, CRL7030, HsS78Bst, PER.C6, SP2/0-Agl4, and hybridoma cells.

In another aspect, the present invention provides a method of treating a subject having an CD137L-associated disease or disorder, the method comprising administering to the subject an effective amount of the CD137 receptor agonist protein. In one embodiment, the CD137 receptor agonist protein is administered alone. In another embodiment, the CD137 receptor agonist protein is administered before, concurrently, or after the administration of a second agent. In another embodiment, the disease or disorder is selected from the group consisting of: tumors, infectious diseases, inflammatory diseases, metabolic diseases, autoimmune disorders, degenerative diseases, apoptosis-associated diseases, and transplant rejections. In one embodiment, the tumors are solid tumors. In one embodiment, the tumors arise from the group of cancers consisting of sarcoma, esophageal cancer, and gastric cancer. In another embodiment, the tumors arise from Ewing's sarcoma or fibrosarcoma, In another embodiment, the tumors arise from the group of cancers consisting of Non-Small Cell Lung Carcinoma (NSCLC), pancreatic cancer, colorectal cancer, breast cancer, ovarian cancer, head and neck cancers, and Small Cell Lung Cancer (SCLC). In another embodiment, the tumors are lymphatic tumors. In one embodiment, the tumors are hematologic tumors.

In another embodiment, the tumors arise from non-Hodgkin's lymphoma, leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B cell lymphoma, Burkitt's lymphoma, chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), or hairy cell leukemia. In another embodiment, the autoimmune disorders are
5 rheumatoid diseases, arthritic diseases, or rheumatoid and arthritic diseases. In a further embodiment, the disease or disorder is rheumatoid arthritis. In another embodiment, the degenerative disease is a neurodegenerative disease. In a further embodiment, the neurodegenerative disease is multiple sclerosis.

10 In one embodiment, the second agent is a chemotherapeutic, radiotherapeutic, or biological agent. In one embodiment, the second agent is selected from the group consisting of Duvelisib, Ibrutinib, Navitoclax, and Venetoclax. In another embodiment, the second agent is an apoptotic agent. In one embodiment, the apoptotic second agent is selected from the group consisting of Bortezomib, Azacitidine, Dasatinib, and
15 Gefitinib. In a particular embodiment, the pharmaceutical compositions disclosed herein are administered to a patient by intravenous or subcutaneous administration. In other embodiments, the disclosed pharmaceutical compositions are administered to a patient by oral, parenteral, intramuscular, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracerebellar,
20 intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal administration.

25 In one embodiment, the CD137 receptor agonist protein is administered as a single bolus. In another embodiment, CD137 receptor agonist protein may be administered over several divided doses. The CD137 receptor agonist protein can be administered at about 0.1-100 mg/kg. In one embodiment, the CD137 receptor agonist protein can be
30 administered at a dosage selected from the group consisting of: about 0.1-0.5, 0.1-1, 0.1-10, 0.1-20, 0.1-50, 0.1-75, 1-10, 1-15, 1-7.5, 1.25-15, 1.25-7.5, 2.5-7.5, 2.5-15, 5-

15, 5-7.5, 1-20, 1-50, 7-75, 1-100, 5-10, 5-15, 5-20, 5-25, 5-50, 5-75, 10-20, 10-50, 10-75, and 10-100 mg/kg. In other embodiments, the CD137 receptor agonist protein is present in pharmaceutical compositions at about 0.1-100 mg/ml. In one embodiment, the CD137 receptor agonist protein is present in pharmaceutical compositions at an amount selected from the group consisting of: about 0.1-0.5, 0.1-1, 0.1-10, 0.1-20, 0.1-50, 0.1-75, 1-10, 1-20, 1-50, 1-75, 1-100, 5-10, 5-15, 5-20, 5-25, 5-50, 5-75, 10-20, 10-50, 10-75, or 10-100 mg/ml. In other embodiments, a therapeutically effective amount of CD137 receptor agonist protein is administered to a subject. In another embodiment, a prophylactically effective amount of CD137 receptor agonist protein is administered to a subject.

The term "CD137L-associated disease or disorder" as used herein is any disease or disorder which may be ameliorated by administering an effective amount of a CD137 receptor agonist to a subject in need thereof. At least one CD137 receptor agonist protein, respective nucleic acid encoding therefore, or transformed or transfected cell, all as described herein may be used in therapy, *e.g.*, in the prophylaxis and/or treatment of disorders caused by, associated with and/or accompanied by dysfunction of CD137L, particularly proliferative disorders, such as tumors, *e.g.* solid or lymphatic tumors; infectious diseases; inflammatory diseases; metabolic diseases; autoimmune disorders, *e.g.* rheumatoid and/or arthritic diseases; degenerative diseases, *e.g.* neurodegenerative diseases such as multiple sclerosis; apoptosis-associated diseases or transplant rejections.

The term "dysfunction of CD137L" as used herein is to be understood as any function or expression of CD137L that deviates from the normal function or expression of CD137L, *e.g.*, overexpression of the CD137L gene or protein, reduced or abolished expression of the CD137L gene or protein compared to the normal physiological expression level of CD137L, increased activity of CD137L, reduced or abolished activity of CD137L, increased binding of CD137L to any binding partners, *e.g.*, to a receptor, particularly a CD137L receptor or another cytokine molecule, reduced or abolished binding to any

binding partner, e.g. to a receptor, particularly a CD137L receptor or another cytokine molecule, compared to the normal physiological activity or binding of CD137L.

In various embodiments, a method is provided for diagnosing and/or treating a human subject suffering from a disorder which can be diagnosed and/or treated by targeting

5 CD137L receptors comprising administering to the human subject a CD137 receptor agonist protein disclosed herein such that the effect on the activity of the target, or targets, in the human subject is agonistic, one or more symptoms is alleviated, and/or treatment is achieved. The CD137 receptor agonist proteins provided herein can be used to diagnose and/ or treat humans suffering from primary and metastatic cancers, 10 including carcinomas of breast, colon, rectum, lung (e.g., small cell lung cancer "SCLC" and non- small cell lung cancer "NSCLC"), oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male 15 genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma), tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, 20 neuroblastomas, Schwannomas, and meningiomas), tumors arising from hematopoietic malignancies, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B cell lymphoma, Burkitt's lymphoma, chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, Hodgkin's and non-Hodgkin's lymphomas, DLBCL, follicular lymphomas, hematopoietic malignancies, 25 Kaposi's sarcoma, malignant lymphoma, malignant histiocytosis, malignant melanoma, multiple myeloma, paraneoplastic syndrome/hypercalcemia of malignancy, or solid tumors.

A pharmaceutical composition comprising a CD137 receptor agonist protein disclosed herein and a pharmaceutically acceptable carrier is provided. In some embodiments, 30 the pharmaceutical composition comprises at least one additional therapeutic agent for treating a disorder. For example, the additional agent may be a therapeutic agent, a

chemotherapeutic agent; an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor (including but not limited to a KDR and a TIE-2 inhibitor), a co-stimulation molecule modulator or an immune checkpoint inhibitor (including but not limited to anti-B7.1, anti-B7.2, anti-B7.3, anti-B7.4, anti-CD28, anti-B7RP1, CTLA4-Ig, anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-ICOS, anti-LAG-3, anti-Tim3, anti-VISTA, anti-HVEM, anti-BTLA, LIGHT fusion protein, anti-CD137, anti-CD137L, anti-OX40, anti-OX40L, anti-CD70, anti-CD27, anti-CD27L, anti-GAL9, anti-A2AR, anti-KIR, anti-IDO-1, anti-CD20), a dendritic cell/antigen-presenting cell modulator (including but not limited to anti-CD40 antibody, anti-CD40L, anti-DC-SIGN, anti-Dectin-1, anti-CD301, anti-CD303, anti-CD123, anti-CD207, anti-DNGR1, anti-CD205, anti-DCIR, anti-CD206, anti-ILT7), a modulator for Toll-like receptors (including but not limited to anti-TLR-1, anti-TLR-2, anti-TLR-3, anti-TLR-4, anti-TLR-4, anti-TLR-5, anti-TLR-6, anti-TLR-7, anti-TLR-8, anti-TLR-9), an adhesion molecule blocker (including but not limited to an anti-LFA-1 antibody, an anti-E/L selectin antibody, a small molecule inhibitor), an anti-cytokine antibody or functional fragment thereof (including but not limited to an anti-IL-18, an anti-TNF, or an anti-IL-6/cytokine receptor antibody), a bispecific redirected T cell or NK cell cytotoxicity (including but not limited to a BiTE®), a chimeric T cell receptor (CAR-T) based therapy, a T cell receptor (TCR)-based therapy, a therapeutic cancer vaccine, methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

In an embodiment, a method of treating a cancer or in the prevention or inhibition of metastases from the tumors described herein, the CD137 receptor agonist protein(s) can be used alone or in combination with one or more additional agents, e.g., a chemotherapeutic, radiotherapy, or biological agent. In some embodiments, the agent can include the following: 13-cis-Retinoic Acid; 2-CdA; 2-Chlorodeoxyadenosine; 5-

Azacitidine; 5-Fluorouracil; 5-FU; 6-Mercaptopurine; 6-MP; 6-TG; 6-Thioguanine;
 Abraxane; Accutane®; Actinomycin-D; Adriamycin®; Adrucil®; Afinitor®; Agrylin®; Ala-
 Cort®; Aldesleukin; Alemtuzumab; ALIMTA; Alitretinoin; Alkaban-AQ®; Alkeran®; All-
 transretinoic Acid; Alpha Interferon; Altretamine; Amethopterin; Amifostine;
 5 Aminogluthethimide; Anagrelide; Anandron®; Anastrozole; Arabinosylcytosine; Ara-C
 Aranesp®; Aredia®; Arimidex®; Aromasin®; Arranon®; Arsenic Trioxide; Arzerra™;
 Asparaginase; ATRA; Avastin®; Azacitidine; BCG; BCNU; Bendamustine;
 Bevacizumab; Bexarotene; BEXXAR®; Bicalutamide; BiCNU; Blenoxane®; Bleomycin;
 Bortezomib; Busulfan; Busulfex®; C225; Calcium Leucovorin; Campath®; Camptosar®;
 10 Camptothecin-11; Capecitabine Carac™; Carboplatin; Carmustine; Carmustine Wafer;
 Casodex®; CC-5013; CCI-779; CCNU; CDDP; CeeNU; Cerubidine®; Cetuximab;
 Chlorambucil; Cisplatin; Citrovorum Factor; Cladribine; Cortisone; Cosmegen®; CPT-
 11; Cyclophosphamide; Cytadren®; Cytarabine; Cytarabine Liposomal; Cytosar-U®;
 Cytosan®; Dacarbazine; Dacogen; Dactinomycin; Darbepoetin Alfa; Dasatinib;
 15 Daunomycin; Daunorubicin; Daunorubicin Hydrochloride; Daunorubicin Liposomal;
 DaunoXome®; Decadron; Decitabine; Delta-Cortef®; Deltasone®; Denileukin; Diffitox;
 DepoCyt™; Dexamethasone; Dexamethasone Acetate; Dexamethasone Sodium
 Phosphate; Dexasone; Dexrazoxane; DHAD; DIC; Diodex; Docetaxel; Doxil®;
 Doxorubicin; Doxorubicin Liposomal; Droloxia™; DTIC; DTIC-Dome®; Duralone®;
 20 Duvelisib; Efudex®; Eligard™; Ellence™; Eloxatin™; Elspar®; Emcyf®; Epirubicin;
 Epoetin Alfa; Erbitux; Erlotinib; Erwinia L-asparaginase; Estramustine; Ethyol
 Etopophos®; Etoposide; Etoposide Phosphate; Eulexin®; Everolimus; Evista®;
 Exemestane; Fareston®; Faslodex®; Femara®; Filgrastim; Floxuridine; Fludara®;
 Fludarabine; Fluoroplex®; Fluorouracil; Fluorouracil (cream); Fluoxymesterone;
 25 Flutamide; Folinic Acid; FUDR®; Fulvestrant; Gefitinib; Gemcitabine; Gemtuzumab
 ozogamicin; Gemzar; Gleevec™; Gliadel® Wafer; GM-CSF; Goserelin; Granulocyte-
 Colony Stimulating Factor (G-CSF); Granulocyte Macrophage Colony Stimulating
 Factor (G-MCSF); Halotestin®; Herceptin®; Hexadrol; Hexalen®;
 Hexamethylmelamine; HMM; Hycamtin®; Hydrea®; Hydrocort Acetate®;
 30 Hydrocortisone; Hydrocortisone Sodium Phosphate; Hydrocortisone Sodium Succinate;
 Hydrocortone Phosphate; Hydroxyurea; Ibrutinib; Ibritumomab; Ibritumomab Tiuxetan;

Idamycin®; Idarubicin Ifex®; Interferon-alpha; Interferon-alpha-2b (PEG Conjugate); Ifosfamide; Interleukin-11 (IL-11); Interleukin-2 (IL-2); Imatinib mesylate; Imidazole Carboxamide; Intron A®; ipilimumab, Iressa®; Irinotecan; Isotretinoin; Ixabepilone; Ixempra™; KADCYCLA®; Kidrolase (t) Lanacort®; Lapatinib; L-asparaginase; LCR; 5 Lenalidomide; Letrozole; Leucovorin; Leukeran; Leukine™; Leuprolide; Leurocristine; Leustatin™; Lirilumab; Liposomal Ara-C; Liquid Pred®; Lomustine; L-PAM; L-Sarcosine; Lupron®; Lupron Depot®; Matulane®; Maxidex; Mechlorethamine; Mechlorethamine Hydrochloride; Medrolone®; Medrol®; Megace®; Megestrol; Megestrol Acetate; MEK inhibitors; Melphalan; Mercaptopurine; Mesna; Mesnex™; 10 Methotrexate; Methotrexate Sodium; Methylprednisolone; Meticorten®; Mitomycin; Mitomycin-C; Mitoxantrone M-Prednisol®; MTC; MTX; Mustargen®; Mustine; Mutamycin®; Myleran®; Mylocel™; Mylotarg®; Navitoclax; Navelbine®; Nelarabine; Neosar®; Neulasta™; Neumega®; Neupogen®; Nexavar®; Nilandron®; Nilotinib; Nilutamide; Nipent®; Nitrogen Mustard Novaldex®; Nivolumab; Novantrone®; Nplate; 15 Octreotide; Octreotide acetate; Ofatumumab; Oncospar®; Oncovin®; Ontak®; Onxal™; Oprelvekin; Orapred®; Orasone®; Oxaliplatin; Paclitaxel; Paclitaxel Protein-bound; Pamidronate; Panitumumab; Panretin®; Paraplatin®; Pazopanib; Pediapred®; PEG Interferon; Pegaspargase; Pegfilgrastim; PEG-INTRON™; PEG-L-asparaginase; PEMETREXED; Pembrolizumab; Pentostatin; Pertuzumab; Phenylalanine Mustard; 20 Pidilizumab; Platinol®; Platinol-AQ®; Prednisolone; Prednisone; Prelone®; Procarbazine; PROCIT®; Proleukin®; Prolifeprospan 20 with Carmustine Implant; Purinethol®; BRAF inhibitors; Raloxifene; Revlimid®; Rheumatex®; Rituxan®; Rituximab; Roferon-A®; Romiplostim; Rubex®; Rubidomycin hydrochloride; Sandostatin®; Sandostatin LAR®; Sargramostim; Solu-Cortef®; Solu-Medrol®; 25 Sorafenib; SPRYCEL™; STI-571; STIVAGRA™, Streptozocin; SU11248; Sunitinib; Sutent®; Tamoxifen Tarceva®; Targretin®; Tassigna®; Taxol®; Taxotere®; Temodar®; Temozolomide Temsirolimus; Teniposide; TESPAs; Thalidomide; Thalomid®; TheraCys®; Thioguanine; Thioguanine Tabloid®; Thiophosphoamide; Thioplex®; Thiotepa; TICE®; Toposar®; Topotecan; Toremifene; Torisel®; Tositumomab; 30 Trastuzumab; Treanda®; Tremelimumab; Tretinoin; Trexall™; Trisenox®; TSPA; TYKERB®; Urelumab; VCR; Vectibix™; Velban®; Velcade®; Venetoclax; VePesid®;

Vesanoid®; Viadur™; Vidaza®; Vinblastine; Vinblastine Sulfate; Vincasar Pfs®; Vincristine; Vinorelbine; Vinorelbine tartrate; VLB; VM-26; Vorinostat; Votrient; VP-16; Vumon®; Xeloda®; Zanosar®; Zevalin™; Zinecard®; Zoladex®; Zoledronic acid; Zolinza; or Zometa®, and/or any other agent not specifically listed here that target
5 similar pathways.

When two or more substances or principles are to be used as part of a combined treatment regimen, they can be administered via the same route of administration or via different routes of administration, at essentially the same time or at different times (*e.g.* essentially simultaneously, consecutively, or according to an alternating regime). When
10 the substances or principles are to be administered simultaneously via the same route of administration, they may be administered as different pharmaceutical formulations or compositions or part of a combined pharmaceutical formulation or composition, as will be clear to the skilled person.

Also, when two or more active substances or principles are to be used as part of a
15 combined treatment regimen, each of the substances or principles may be administered in the same amount and according to the same regimen as used when the compound or principle is used on its own, and such combined use may or may not lead to a synergistic effect. However, when the combined use of the two or more active substances or principles leads to a synergistic effect, it may also be possible to reduce
20 the amount of one, more than one, or all of the substances or principles to be administered, while still achieving the desired therapeutic action. This may, *e.g.*, be useful for avoiding, limiting or reducing any unwanted side-effects that are associated with the use of one or more of the substances or principles when they are used in their usual amounts, while still obtaining the desired pharmaceutical or therapeutic effect.

25 The effectiveness of the treatment regimen used according to the invention may be determined and/or followed in any manner known per se for the disease or disorder involved, as will be clear to the clinician. The clinician will also be able, where appropriate and on a case-by-case basis, to change or modify a particular treatment regimen, so as to achieve the desired therapeutic effect, to avoid, limit or reduce
30 unwanted side-effects, and/or to achieve an appropriate balance between achieving the

desired therapeutic effect on the one hand and avoiding, limiting or reducing undesired side effects on the other hand.

Generally, the treatment regimen will be followed until the desired therapeutic effect is achieved and/or for as long as the desired therapeutic effect is to be maintained. Again,
5 this can be determined by the clinician.

In various embodiments, pharmaceutical compositions comprising one or more CD137 receptor agonist proteins, either alone or in combination with prophylactic agents, therapeutic agents, and/or pharmaceutically acceptable carriers are provided herein. In
10 various embodiments, nonlimiting examples of the uses of the pharmaceutical compositions disclosed herein include diagnosing, detecting, and/or monitoring a disorder, preventing, treating, managing, and/or ameliorating a disorder or one or more symptoms thereof, and/or in research. The formulation of pharmaceutical compositions, either alone or in combination with prophylactic agents, therapeutic agents, and/or
15 pharmaceutically acceptable carriers, are known to one skilled in the art (US Patent Publication No. 20090311253 A1).

As used herein, the phrase "effective amount" means an amount of CD137L agonist protein that results in a detectable improvement (*e.g.*, at least about 5%, 10%, 15%,
20 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more from baseline) in one or more parameters associated with a dysfunction of CD137L or with a CD137L-associated disease or disorder.

Methods of administering a therapeutic agent provided herein include, but are not
25 limited to, oral administration, parenteral administration (*e.g.*, intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural administration, intratumoral administration, mucosal administration (*e.g.*, intranasal and oral routes) and pulmonary administration (*e.g.*, aerosolized compounds administered with an inhaler or nebulizer). The formulation of pharmaceutical compositions for specific routes of administration,
30 and the materials and techniques necessary for the various methods of administration

are available and known to one skilled in the art (US Patent Publication No. 20090311253 A1).

In various embodiments, dosage regimens may be adjusted to provide for an optimum
5 desired response (e.g., a therapeutic or prophylactic response). For example, a single
bolus may be administered, several divided doses may be administered over time or the
dose may be proportionally reduced or increased as indicated by the exigencies of the
therapeutic situation. In some embodiments, parenteral compositions are formulated in
dosage unit form for ease of administration and uniformity of dosage. The term "dosage
10 unit form" refers to physically discrete units suited as unitary dosages for the
mammalian subjects to be treated; each unit containing a predetermined quantity of
active compound calculated to produce the desired therapeutic effect in association with
the required pharmaceutical carrier.

An exemplary, non-limiting range for a therapeutically or prophylactically effective
15 amount of a CD137 receptor agonist protein provided herein is about 0.1-100 mg/kg,
(e.g., about 0.1-0.5, 0.1-1, 0.1-10, 0.1-20, 0.1-50, 0.1-75, 1-10, 1-15, 1-7.5, 1.25-15,
1.25-7.5, 2.5-7.5, 2.5-15, 5-15, 5-7.5, 1-20, 1-50, 7-75, 1-100, 5-10, 5-15, 5-20, 5-25, 5-
50, 5-75, 10-20, 10-50, 10-75, or 10-100 mg/kg, or any concentration in between). In
some embodiments, the CD137 receptor agonist protein is present in a pharmaceutical
20 composition at a therapeutically effective concentration, e.g., a concentration of about
0.1-100 mg/ml (e.g., about 0.1-0.5, 0.1-1, 0.1-10, 0.1-20, 0.1-50, 0.1-75, 1-10, 1-20, 1-
50, 1-75, 1-100, 5-10, 5-15, 5-20, 5-25, 5-50, 5-75, 10-20, 10-50, 10-75, or 10-100
mg/ml, or any concentration in between). Note that dosage values may vary with the
type and/or severity of the condition to be alleviated. It is to be further understood that
25 for any particular subject, specific dosage regimens may be adjusted over time
according to the individual need and/or the professional judgment of the person
administering or supervising the administration of the compositions, and that dosage
ranges set forth herein are exemplary only and are not intended to limit the scope or
practice of the claimed composition.

Examples

1.1 Polypeptide structure

- A) Amino acids Met1 – Gly20
5 Ig-Kappa-signal peptide, assumed signal peptidase cleavage site after amino acid Gly 20.
- B) Amino acids Gln21 – Val172
10 First soluble cytokine domain of the human CD137L ligand (CD137L, amino acid 89 - 240 of SEQ ID NO: 1).
- C) Amino acids Gly173 – Ser 180
First peptide linker element of SEQ ID NO: 2.
- 15 D) Amino acids Gln181 – Val332
Second soluble cytokine domain of the human CD137L ligand (CD137L, amino acid 89 - 240 of SEQ ID NO: 1).
- 20 E) Amino acids Gly333 – Ser340.
Second peptide linker element of SEQ ID NO: 2.
- F) Amino acids Gln341 – Val492
25 Third soluble cytokine domain of the human CD137L ligand (CD137L, amino acid 89 - 240 of SEQ ID NO: 1).
- G) Amino acids Gly493 – Cys513
Hinge-linker element of SEQ ID NO: 16.
- 30 H) Amino acids Pro514 – Lys731

Antibody Fc fragment domain of SEQ ID NO: 13.

The above CD137 receptor agonist protein is shown in SEQ ID NO: 25.

- 5 The indicated linkers may be replaced by other preferred linkers, *e.g.* as shown in SEQ ID NOs: 3-12.

The indicated Hinge-linker element may be replaced by other preferred Hinge-linkers, *e.g.* as shown in SEQ ID NOs: 19-24.

10

It should be noted that the first and second peptide linkers do not need to be identical.

The signal peptide sequence (A) may be replaced by any other suitable, *e.g.* mammalian signal peptide sequence.

15

1.2 Gene cassette encoding the polypeptide

The synthetic gene may be optimized in view of its codon usage for the expression in suitable host cells, *e.g.* insect cells or mammalian cells. A preferred nucleic acid
20 sequence is shown in SEQ ID NO: 37.

Example 2. Expression and Purification

2.1 Cloning, expression and purification of fusion polypeptides

- 25 The aforementioned fusion proteins are expressed recombinantly in different eukaryotic host cells employing the methods described below:

Method for small scale expression of CD137 receptor agonist fusion proteins:

- For small scale analysis of aforementioned CD137 receptor agonist fusion proteins,
30 Hek293 cells are grown in DMEM + GlutaMAX (GibCo) supplemented with 10% FBS,

100 units/ml Penicillin and 100 [mu]g/ml Streptomycin and are transiently transfected with a plasmid containing an expression cassette for a fusion polypeptide and an appropriate selection marker, e.g. a functional expression cassette comprising a blasticidine, puromycin or hygromycin resistance gene. In those cases, where a plurality
5 of polypeptide chains is necessary to achieve the final product, the expression cassettes are either combined on one plasmid or positioned on different plasmids during the transfection. Cell culture supernatant containing recombinant fusion polypeptide are harvested three days post transfection and clarified by centrifugation at 300 x g followed by filtration through a 0.22 µm sterile filter.

Method for large scale expression and purification of CD137 receptor agonist fusion proteins

For larger scale expression of CD137 receptor agonist fusion proteins, synthetic DNA cassettes encoding the aforementioned proteins are inserted into eukaryotic expression
15 vectors comprising appropriate selection markers (e.g. a functional expression cassette comprising a blasticidin, puromycin or hygromycin resistance gene) and genetic elements suitable to enhance the number of transcriptionally active insertion sites within the host cells genome. The sequence verified expression vectors is introduced by electroporation into suspension adapted Chinese Hamster Ovary cells (CHO-S,
20 Invitrogen). Appropriate selection pressure will be applied three days post-transfection to transfected cells. Surviving cells carrying the vector derived resistance gene(s) are recovered by subsequent cultivation under selection pressure. Upon stable growth of the selected cell pools in chemically defined medium (PowerCHO2-CD, Lonza) at 37°C and 7% CO2 atmosphere in an orbital shaker incubator (100 rpm, 50mm shaking
25 throw), the individual supernatants are analyzed by ELISA-assays detecting the aforementioned proteins and the cell pools with the highest specific productivity are expanded in shake flasks prior to protein production (orbital shaker, 100 rpm, shaking throw 50mm).

30 For lab-scale protein production, individual cell pools are cultured for 7-12 days in chemically defined medium (PowerCHO2-CD, Lonza) at 37°C and 7% CO2 atmosphere

in a Wave bioreactor 20/50 EHT (GE-Healthcare). The basal medium is PowerCHO2-CD supplemented with 4mM Glutamax. Wave culture is started with a viable cell concentration of 0.3 to 0.4 x 10⁶ cells/ml and the following settings (for a five- or ten liter bag): shaking frequency 18rpm, shaking ankle 7°, gas current 0.2-0.3 L/min, 7% CO₂, 36.5°C. During the Wave run, the cell culture is fed twice with PowerFeed A (Lonza), usually on day 2 (20% feed) and day 5 (30% feed). After the second feed, shaking frequency is increased to 22rpm, as well as the shaking ankle to 8°.

The bioreactor is usually harvested in between day 7 to day 12 when the cell viability drops below 80%. First, the culture supernatant is clarified using a manual depth filtration system (Millipore Millistak Pod, MC0HC 0.054m²). For Strep-tagged proteins, Avidin is added to a final concentration of 0.5mg/L. Finally, the culture supernatant containing the CD137 receptor agonist fusion protein is sterile filtered using a bottle top filter (0.22µm, PES, Corning) and stored at 2-8°C until further processing.

For affinity purification Streptactin Sepharose is packed to a column (gel bed 2 ml), equilibrated with 15 ml buffer W (100 mM Tris-HCl, 150 mM NaCl, pH 8.0) or PBS pH 7.4 and the cell culture supernatant is applied to the column with a flow rate of approx. 4 ml/min. Subsequently, the column is washed with 15 ml buffer W and bound polypeptide is eluted stepwise by addition of 7 x 1 ml buffer E (100 mM Tris HCl, 150 mM NaCl, 2.5 mM Desthiobiotin, pH 8.0). Alternately, PBS pH 7.4 containing 2.5 mM Desthiobiotin can be used for this step.

Alternately to the Streptactin Sepharose based method, the affinity purification is performed employing a column with immobilized Protein-A as affinity ligand and an Akta chromatography system (GE-Healthcare). A solid phase material with high affinity for the FC-domain of the fusion protein is chosen: MABSelect SureTM (GE Healthcare). Briefly, the clarified cell culture supernatant is loaded on a HiTrap MabSelectSure column (CV=5ml) equilibrated in wash-buffer-1 (20 mM Pi, 95 mM NaCl, pH7.2) not exceeding a load of 10mg fusion protein per ml column-bed. The column is washed with ten column-volumes (10CV) of aforementioned equilibration buffer followed by four

column-volumes (4CV) of wash-buffer-2 (20mM Pi, 95mM NaCl, pH 8.0) to deplete host-cell protein and host-cell DNA. The column is then eluted with elution buffer (20mM Pi, 95mM NaCl, pH 3.5) and the eluate is collected in up to ten fractions with each fraction having a volume equal to column-bed volume (5ml). Each fraction is neutralized
5 with an equal volume of aforementioned wash-buffer-2. The linear velocity is set to 150cm/h and kept constant during the aforementioned affinity chromatography method. The protein amount of the eluate fractions is quantitated and peak fractions are concentrated by ultrafiltration and further purified by size exclusion chromatography (SEC).

10 SEC is performed on Superdex 200 10/300 GL or HiLoad 26/60 columns using an Akta chromatography system (GE-Healthcare). The columns are equilibrated with phosphate buffered saline and the concentrated, affinity-purified polypeptide is loaded onto the SEC column with the sample volume not exceeding 2 % (v/v) of the column-volume. In
15 the case of Superdex 200 10/300 GL columns (GE Healthcare), a flow rate of 0.5ml per minute is applied. In the case of HiLoad 26/60 Superdex200 columns, a flow rate of 2.5 ml per minute is applied. The elution profile of the polypeptide is monitored by absorbance at 280 nm.

For determination of the apparent molecular weight of purified fusion polypeptide under
20 native conditions a Superdex 200 column is loaded with standard proteins of known molecular weight. Based on the elution volume of the standard proteins a calibration curve is plotted and the molecular weight of purified fusion polypeptide is determined. The FC-domain comprising CD137 receptor agonist fusion proteins elutes from the Superdex200 columns with an apparent molecular weight of approx. 140-180 kDa,
25 which would confirm the homodimerization of the mature CD137 receptor agonist fusion polypeptide by the Fc domain.

Example 3: Trivalent Control Protein

To compare the relative binding between hexavalent CD137 receptor agonist fusion
30 proteins and the, homo-trimeric trivalent CD137 receptor agonist fusion proteins

stabilized with bacteriophage RB69-FOLDON is expressed in CHO-S cells and purified as described in the former section. The sequence is shown in the table below:

SEQ ID NO	Sequence
38 (Trivalent control protein)	METDTLLVFVLLVWVPAGNGQGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGL SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLG LFRVGSGSSGSSGSSGSGYIEDAPSDGKFYVRKDGAWVELPTASGPSSSSSSSAWSH PQFEK.

5 **Example 4: Determination of the in vitro stability of CD137 receptor agonist proteins by limited protease digestion**

All CD137 receptor agonist proteins to be investigated will be expressed and purified as hexavalent Fc-Fusion protein as described in Example 1. The set will include CD137 receptor agonist proteins comprising the N297S mutation [according to the EU numbering system] in the CH2-domain and a hinge region that enables the formation of three disulfide bridges and additionally lack the upper hinge lysine [K223, according to the EU numbering system] which is mutated to glycine [K223G]. In a limited protease digestion assay, the aforementioned CD137 receptor agonist proteins comprising the N297S mutation and the K223G mutation simultaneously in context of a three disulfide enabling hinge will be compared to CD137 receptor agonist proteins comprising the N297S mutation but have the K223 wildtype present either in the context of a two disulfide or three disulfide enabling hinge region.

In addition CD137 receptor agonist proteins with the second linker element (iv) reduced to 4 amino-acids and the shortened hinge element (vi) will be investigated (e.g. SEQ ID NO: 32 and 34). Both engineering strategies (N297S combined with K223G mutation in context of a three disulfide enabling hinge region) and shortage of linker elements (iv and vi) have a potential impact on the stability of the respective molecules.

The stability of different CD137 agonistic proteins of the present invention can be addressed by limited protease digestion in vitro. For this analysis, the aforementioned

CD137 receptor agonist proteins are incubated with low concentrations of proteases (e.g. Trypsin, V8 protease) at different temperatures (e.g. 4°C, 25°C, 37°C) for different amounts of time. Quantification of specific proteolytic fragments and their appearance over time can be subsequently measured by different methods, like SDS-PAGE, analytical SEC or analytical Mass-Spectrometry methods known in the art (e.g Nano-RP-HPLC-ESI-MSMS). As the investigated proteins have most of their sequences in common, the faster appearance and enlarged quantities of specific proteolytic fragments from individual proteins over time can then be used to judge their relative stability and rank them to each other. With regard to protease based decoy kinetics of the aforementioned CD137 receptor agonist proteins investigated, the following order regarding their proteolytic stability is to be expected:

The CD137 receptor agonist proteins comprising the N297S and the K223G and the three disulfide enabling hinge region simultaneously have a prolonged stability as compared to the CD137 receptor agonist proteins comprising the N297S and wildtype K223 in the hinge region. The CD137 receptor agonist proteins comprising the SEQ ID NO: 21 as hinge linker have a prolonged stability as compared to CD137 receptor agonist proteins comprising the SEQ ID NO: 16 as hinge linker element.

Example 5: Stability/Aggregation Test

The contents of monomers and aggregates are determined by analytical SEC as described in Example 2. For this particular purpose the analysis is performed in buffers containing physiological salt concentrations at physiological pH (e.g. 0.9% NaCl, pH 7.4; PBS pH 7.4). A typical aggregation analysis is done on a Superdex200 column (GE Healthcare). This column separates proteins in the range between 10 to 800 kDa.

For determination of the apparent molecular weight of purified fusion polypeptide under native conditions a Superdex 200 column is loaded with standard proteins of known molecular weight. Based on the elution volume of the standard proteins a calibration curve is plotted and the apparent molecular weight of purified fusion proteins of unknown molecular weight is calculated based on the elution volume.

SEC analysis of soluble, non-aggregated protein typically shows a distinct single protein peak at a defined elution volume (measured at OD at 280nm or at OD 214nm). This elution volume corresponds to the apparent native molecular weight of the particular protein. With regard to the definition of “monomer” in the case of FC-fusion proteins, the assembly of two polypeptide-chains is driven by the FC-part of the protein and the functional unit is a protein consisting of two chains. This unit that contains two FC-linked polypeptide chains is defined as “monomer” in the case of Fc-fusion proteins regardless of being a dimerized single-chain fusion polypeptide.

If protein aggregation occurs, the SEC analysis shows additional protein peaks with lower retention volumes. Protein oligomers potentially serve as aggregation seeds and a high content of oligomers potentially leads to aggregation of the protein. Oligomers of large molecular weight and aggregates elute in the void volume of the Superdex200 column and cannot be analyzed by SEC with respect to their native molecular weight.

Purified preparations of CD137 receptor agonist fusion proteins should preferably contain only defined monomeric protein and only a very low amount of oligomeric protein. The degree of aggregation/oligomerization of a particular CD137 receptor agonist fusion protein preparation is determined on basis of the SEC analysis by calculating the peak areas of the OD280 diagram for the defined monomer and the oligomer/aggregate fraction, respectively.. Based on the total peak area the percentage of defined monomer protein is calculated as follows:

monomer content [%] = [Peak area monomer protein] / [Total peak area] x 100)

Example 6: Determination of the equilibrium binding constants for tri- and hexavalent CD137 receptor ligand constructs by QCM analysis

The equilibrium binding constants (K_D) of trivalent and hexavalent constructs of CD137 receptor ligand are calculated based on kinetic binding data (k_{on} and k_{off}) that are determined with an automated biosensor system (Attana A100). The A100 allows to investigate molecular interactions in real-time based on the Quartz Crystal Microbalance (QCM) technique.

For this purpose the human CD137 receptor is immobilized to the surface of a carboxyl-activated QCM-chip. Subsequently the tri- or hexavalent CD137 receptor ligand, respectively, is used as an analyte at different concentrations (e.g. 0.5, 1, 2, 5, and 10 µg/ml) for analyzing the kinetic binding data for ligand-receptor binding (k_{on}) and dissociation (k_{off}). The analysis is done in real time and the respective K_D can be calculated: $K_D = k_{off} / k_{on}$.

The QCM analysis shows that the trivalent CD137 receptor ligand binds to the respective immobilized CD137 receptor with a K_D in the low nM-range with an expected K_D of 1 – 500nM. However, hexavalent constructs of CD137 receptor ligand show a higher binding affinity in the pM-range towards the respective immobilized CD137 receptor with an expected K_D of 1pM – 500 nM. A common characteristic of the kinetic binding data (k_{on} and k_{off}) is that the hexavalent constructs show faster k_{on} in comparison to the trivalent constructs. In addition slower dissociation (k_{off}) is commonly observed for the hexavalent ligands if compared to the trivalent ligand.

Example 7: T Cell Proliferation Assay

To assess the T cell activation capability of the CD137 receptor agonist, T cells are purified from human buffy coat preparations by negative selection using magnetic beads. Cells are labeled with CFSE and incubated with or without varying amounts of the CD137 receptor agonist and combined with an anti-human CD3 antibody for 2-5 days at 37° C. Data on CFSE dilution as a means to measure cell division is acquired on a flow cytometer. IFN γ production is measured by an ELISA assay using cell culture supernatants and an anti-human IFN γ antibody for capture.

One expects to observe a clear augmentation of IFN γ secretion by both CD4+ and CD8+ T cells when the CD137 receptor agonist is present in the T cell cultures along with the anti-human CD3 antibody. As well as higher IFN γ production one expects to see more T cells to be driven into cell cycle by measuring CFSE dilution using flow cytometry. This would demonstrate a co-stimulatory effect of the CD137 receptor agonist in the context of T cell activation.

Example 8: CD137 agonist binding assay

Primary, human T cells are isolated from fresh buffy coat preparations using negative selection and magnetic beads. Cells are seeded into 24-well plates at 2×10^6 cells per well. T cells are incubated with an anti-human CD3 antibody (clone HIT3a, $1 \mu\text{g/ml}$), anti-
5 human CD28 antibody (clone CD28.2, $5 \mu\text{g/ml}$) and varying amounts of Protein A (CD137L, 10-1000ng/ml) or simply left in medium as control. After 3 days at 37°C cells are fluorescently labeled with anti-human CD137 and anti-human CD4 or anti-human CD8 antibodies. CD137 fluorescence is assessed on a guava easyCyte flow cytometer within CD4+ and CD8+ T cell populations.

10 When comparing T cell populations incubated with anti-CD3 and anti-CD28 antibodies to control cells left in medium alone, one expects to observe a lower fluorescent signal for CD137 indicating an activation-induced downregulation of the receptor. This effect can be stronger and dose-dependent, when cells are co-incubated with the CD137 agonist (Protein A), which indicates a supplementary effect caused by the CD137
15 agonist (Protein A). Such results would suggest a binding of the CD137 agonist (Protein A) to its receptor in vitro.

Example 9: Human in vitro T Cell Proliferation Assay

Total T cells (human) purified by negative selection and magnetic beads (pan T cell
20 isolation kit, Miltenyi Biotec) from the peripheral blood of healthy donors and stained with CFSE (CellTrace™ CFSE Cell Proliferation Kit, for flow cytometry, ThermoFisher) and seeded into 24-well plates at 2×10^6 cells per well. Cells were incubated at 37°C for 5 days with media alone, soluble anti-CD3 antibody (clone OKT3 at $1 \mu\text{g/ml}$) alone, anti-CD3 antibody plus anti-CD28 antibody (clone 28.2 at $1 \mu\text{g/ml}$) or anti-CD3 antibody
25 plus mature Protein A (SEQ ID NO: 27) at 10, 100 or 1000 ng/ml, respectively.

On day 5, cells were washed and stained with DAPI (to exclude dead cells) and specific antibodies. Expression of Forward Scatter (FSC or size) and proliferation dependent CFSE dilution was measured by flow cytometry with a Guava EasyCyte 12 Flow
Cytometer (EMD Millipore). Data analysis was performed on a minimum of ten thousand
30 recorded events per sample with FlowJo 10.1 software (FlowJo, LLC). The percentage

of responding cells was determined by gating on Forward Scatter and CFSE using the media control to determine proper gate location. Cells that had either increased cell size or decreased CFSE levels were labeled as responding cells. The individual data from two biological replicates from one donor is shown in below copied table (Quantification of T cell activation) These results are consistent with results from additional donors and clearly showed that treatment of human T cells in vitro with Protein A enhances T cell activation and proliferation as compared to antibody stimulation alone.

Quantification of T cell activation.

Human T cell activation following treatment with Protein A in vitro		
	% of cells responding	
Stimulation	Sample 1	Sample 2
Media	3	3
anti-CD3	56	62
anti-CD3/28	87	85
anti-CD3 + APG1472 10ng/ml	71	69
anti-CD3 + APG1472 100ng/ml	75	71
anti-CD3 + APG1472 1000ng/ml	66	75

Example 10: Receptor Binding Assay

For ELISA assays assessing functional binding of CD137 receptor agonist protein of the invention to its corresponding receptor, coating of microtiter plates was performed with 1 µg/ml CD137-Fc (Bio-Techne GmbH, Wiesbaden-Nordenstadt, Germany). After blocking with StartingBlock (Life Technologies GmbH, Darmstadt, Germany), wells were incubated with indicated concentrations of strep-tagged Protein A (SEQ ID NO: 28).

Binding to its corresponding receptor was detected via its Strep Tag II employing the anti-StrepTag-peroxidase StrepTactin-HRP (1:5000, IBA GmbH, Goettingen, Germany) and subsequent detection of the converted Peroxidase-substrate TMB one (Kem-En-Tec Diagnostics, Taastrup, Denmark) at a wavelength of 450 nm in an ELISA reader.

Fig. 6 clearly depicts concentration dependent binding of Protein A to its receptor.

Claims

1. A CD137 receptor agonist protein comprising a single-chain fusion polypeptide comprising:
 - (i) a first soluble CD137L domain,
 - (ii) a first peptide linker,
 - (iii) a second soluble CD137L domain,
 - (iv) a second peptide linker, and
 - (v) a third soluble CD137L domain, and
 - (vi) a hinge-linker selected from the group consisting of SEQ ID NOs: 16 and 19-24, and
 - (vii) an antibody Fc fragment, wherein the antibody Fc fragment (vii) consists of the amino acid sequence as shown in SEQ ID NO: 13 or amino acids 1-217 of SEQ ID NO: 13.
2. The CD137 receptor agonist protein of claim 1, wherein the antibody Fc fragment (vii) is fused to the C-terminal end of the third CD137L domain (v) via a hinge-linker (vi).
3. The CD137 receptor agonist protein of any one of claims 1-2 which is substantially non-aggregating.
4. The CD137 receptor agonist protein of any one of claims 1-3, wherein the second and/or third soluble CD137L domain is an N-terminally shortened domain which optionally comprises amino acid sequence mutations.
5. The CD137 receptor agonist protein of any one of claims 1-4, wherein at least one of the soluble CD137L domains, particularly at least one of the soluble CD137L domains (iii) and (v), is a soluble CD137L domain with an N-terminal sequence which starts with amino acid D86 or R88 or Q89 or G90 of human CD137L according to SEQ ID NO: 1 and wherein D86 or R88 or Q89 may be replaced by a neutral amino acid, e.g. Ser or Gly.

6. The CD137 receptor agonist protein of claim 5, wherein at least one of the soluble CD137L domains, particularly at least one of the soluble CD137L domains (iii) and (v), is a soluble CD137L domain with an N-terminal sequence selected from
 - (a) D86 – G90 and
 - (b) (Gly/Ser)89 – G90.
7. The CD137 receptor agonist protein of claim 5 or 6, wherein the soluble CD137L domain ends with amino acid E254 of according to SEQ ID NO: 1 and/or optionally comprises a mutation at positions D86, L87, R88, Q89, D112, V118, A154, A174, A176, A188, T241 at two or more of said positions.
8. The CD137 receptor agonist protein of any one of claims 5-7, wherein at least the soluble CD137L domain (iii), is a C-terminal shortened CD137L domain ending with V240 or T241 or E243
9. The CD137 receptor agonist protein of any one of claims 5-8, wherein the soluble CD137L domains (i), (iii) and (v) consist of amino acids 89-240 of human CD137L according to SEQ ID NO: 1.
10. The CD137 receptor agonist protein of any one of the preceding claims, wherein the first and second peptide linkers (ii) and (iv) independently have a length of 3-8 amino acids, particularly a length of 3, 4, 5, 6, 7 or 8 amino acids, and preferably are glycine/serine linkers, optionally comprising an asparagine residue which may be glycosylated.
11. The CD137 receptor agonist protein of claim 10, wherein the first and the second peptide linkers (ii) and (iv) consist of the amino acid sequence according to SEQ ID NO: 2.
12. The CD137 receptor agonist protein of any one of the preceding claims which additionally comprises an N-terminal signal peptide domain, e.g. of SEQ ID NO: 17, which may comprise a protease cleavage site, and/or which additionally comprises a C-terminal element which may comprise and/or

connect to a recognition/purification domain, e.g. a Strep-tag according to SEQ ID NO: 18.

13. The CD137 receptor agonist protein of any one of the preceding claims comprising the amino acid sequence of any one of SEQ ID NOs: 15 25, 27, 28, and 30-35.
14. The CD137 receptor agonist protein of any one of the preceding claims comprising two polypeptides each having the amino acid sequence as set forth in SEQ ID NOs: 27, 30, 32, 33, 34 or 35.
15. The CD137 receptor agonist protein of claim 14, wherein the two polypeptides are covalently linked through three interchain disulfide bonds formed at:
 - a) positions 484, 490 and 493 of SEQ ID NO: 27, 30, 32, 35 or
 - b) positions 489, 490 and 493 of SEQ ID NO: 30, or
 - c) positions 493, 489 and 502 of SEQ ID NO: 31, or
 - d) positions 487, 493 and 496 of SEQ ID NO: 33 or 34.
16. The CD137 receptor agonist protein of claim 14 or 15, comprising one or more N-glycosylated asparagine residues selected from the list of N158 and N318 of SEQ ID NO: 27, N161 and N324 of SEQ ID NO: 30, 31; N159 and N320 of SEQ ID NO: 33 or 34 and N86, N158, N246, N318 and N406 of SEQ ID NO 35.
17. The CD137 receptor agonist protein of any one of the preceding claims, wherein the polypeptide(s) are further post-translationally modified.
18. The CD137 receptor agonist protein of claim 17, wherein the post-translational modification comprises modification of the N-terminal glutamine to pyroglutamate.

19. A nucleic acid molecule encoding a CD137 receptor agonist protein of any one of claims 1-18, preferably in operative linkage with an expression control sequence.
20. An expression vector comprising the nucleic acid molecule of claim 19.
21. A cell or a non-human organism transformed or transfected with a nucleic acid molecule of claim 19 or a vector of claim 20, wherein the cell is e.g. a prokaryotic cell or a eukaryotic cell, preferably a mammalian cell or more preferably a human cell or a Chinese Hamster Ovary (CHO) cell.
22. A pharmaceutical or diagnostic composition comprising as an active agent a CD137 receptor agonist protein of any one of claims 1-19, a nucleic acid molecule of claim 19 or a vector of claim 20.
23. The pharmaceutical or diagnostic composition according to claim 22, further comprising one or more pharmaceutically acceptable carriers, diluents, excipients and/or adjuvants.
24. The pharmaceutical composition according to claim 22 or 23 for use in therapy, more particularly in the prophylaxis and/or treatment of disorders caused by, associated with and/or accompanied by dysfunction of CD137L, particularly proliferative disorders, such as tumors, e.g. solid or lymphatic tumours; infectious diseases; inflammatory diseases; metabolic diseases; autoimmune disorders, e.g. rheumatoid and/or arthritic diseases; degenerative diseases, e.g. neurodegenerative diseases such as multiple sclerosis; apoptosis-associated diseases or transplant rejections.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

Figure 7





Figure 8



SEQUENCE LISTING

<110> Apogenix AG

<120> SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS

<130> scCD137L-WO

<160> 43

<170> BiSSAP 1.3.6

<210> 1

<211> 254

<212> PRT

<213> Homo sapiens

<220>

<223> CD137 ligand WT

<400> 1

```

Met Glu Tyr Ala Ser Asp Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro
1      5      10      15
Pro Ala Pro Arg Ala Arg Ala Cys Arg Val Leu Pro Trp Ala Leu Val
20      25      30
Ala Gly Leu Leu Leu Leu Leu Leu Ala Ala Ala Cys Ala Val Phe
35      40      45
Leu Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser
50      55      60
Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp
65      70      75      80
Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val
85      90      95
Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp
100     105
Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu
115     120     125
Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe
130     135     140
Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser
145     150     155     160
Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala
165     170     175
Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala
180     185     190
Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala
195     200     205
Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His
210     215     220
Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val
225     230     235     240
Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu
245     250

```

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 2

```

Gly Ser Gly Ser Gly Asn Gly Ser
1      5

```

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 3
Gly Ser Gly Ser Gly Ser Gly Ser
1 5

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 4
Gly Gly Ser Gly Ser Gly Ser Gly
1 5

<210> 5
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 5
Gly Gly Ser Gly Ser Gly
1 5

<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 6
Gly Gly Ser Gly
1

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 7
Gly Gly Ser Gly Asn Gly Ser Gly
1 5

<210> 8
<211> 8
<212> PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 8

Gly Gly Asn Gly Ser Gly Ser Gly
1 5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 9

Gly Gly Asn Gly Ser Gly
1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 10

Gly Ser Gly Ser Gly Ser
1 5

<210> 11

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 11

Gly Ser Gly Ser
1

<210> 12

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 12

Gly Ser Gly
1

<210> 13

<211> 218

<212> PRT

<213> Artificial Sequence

eolf-seql.txt

<220>

<223> IGG1-Fc N297S

<400> 13

```

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
1      5      10      15
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
20      25      30
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
35      40      45
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
50      55      60
Glu Gln Tyr Ser Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
65      70      75      80
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
85      90      95
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
100     105     110
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
115     120     125
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
130     135     140
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
145     150     155     160
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
165     170     175
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
180     185     190
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
195     200     205
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
210     215

```

<210> 14

<211> 217

<212> PRT

<213> Artificial Sequence

<220>

<223> IGG1-Fc WT

<400> 14

```

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
1      5      10      15
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
20      25      30
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
35      40      45
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
50      55      60
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
65      70      75      80
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
85      90      95
Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
100     105     110
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
115     120     125
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
130     135     140
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
145     150     155     160
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
165     170     175
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
180     185     190
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln

```

eolf-seql.txt

195
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 210 215 205

<210> 15
 <211> 745
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> PROT A (CD137L Deglyco Fc)

<400> 15
 Met Glu Thr Asp Thr Leu Leu Val Phe Val Leu Leu Val Trp Val Pro
 1 5 10 15
 Ala Gly Asn Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
 20 25 30
 Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
 35 40 45
 Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
 50 55 60
 Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
 65 70 75 80
 Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
 85 90 95
 Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
 100 105 110
 Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
 115 120 125
 Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu
 130 135 140
 Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
 145 150 155 160
 Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser
 165 170 175
 Gly Asn Gly Ser Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
 180 185 190
 Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
 195 200 205
 Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
 210 215 220
 Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
 225 230 235 240
 Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
 245 250 255
 Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
 260 265 270
 Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
 275 280 285
 Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu
 290 295 300
 Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
 305 310 315 320
 Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser
 325 330 335
 Gly Asn Gly Ser Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
 340 345 350
 Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
 355 360 365
 Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
 370 375 380
 Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
 385 390 395 400
 Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
 405 410 415
 Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
 420 425 430

eolf-seql.txt

```

Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
435 440 445
Phe Gly Phe Gln Gly Arg Leu His Leu Ser Ala Gly Gln Arg Leu
450 455 460
Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
465 470 475 480
Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Ser
485 490 495
Ser Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro
500 505 510
Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
515 520 525
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
530 535 540
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
545 550 555 560
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
565 570 575
Glu Glu Gln Tyr Ser Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
580 585 590
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
595 600 605
Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
610 615 620
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
625 630 635 640
Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
645 650 655
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
660 665 670
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
675 680 685
Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
690 695 700
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
705 710 715 720
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Ser Ser Ser Ser Ser
725 730 735
Ala Trp Ser His Pro Gln Phe Glu Lys
740 745

```

<210> 16
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> hinge linker

<400> 16
 Gly Ser Ser Ser Ser Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His
 1 5 10 15
 Thr Cys Pro Pro Cys
 20

<210> 17
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> universal signal peptide

<400> 17
 Met Glu Thr Asp Thr Leu Leu Val Phe Val Leu Leu Val Trp Val Pro
 1 5 10 15

Ala Gly Asn Gly
20

<210> 18
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> serine linker with strep tag

<400> 18
Ser Ser Ser Ser Ser Ser Ala Trp Ser His Pro Gln Phe Glu Lys
1 5 10 15

<210> 19
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> hinge linker

<400> 19
Gly Ser Ser Ser Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr
1 5 10 15
Cys Pro Pro Cys
20

<210> 20
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> hinge linker

<400> 20
Gly Ser Ser Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys
1 5 10 15
Pro Pro Cys

<210> 21
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> hinge linker

<400> 21
Gly Ser Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro
1 5 10 15
Pro Cys

<210> 22
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> hinge linker

<400> 22

Gly Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
1 5 10 15

<210> 23

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> hinge linker

<400> 23

Gly Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
1 5 10 15
Gly Ser

<210> 24

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> hinge linker

<400> 24

Gly Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
1 5 10 15
Gly Ser Gly Ser
20

<210> 25

<211> 731

<212> PRT

<213> Artificial Sequence

<220>

<223> PROTEIN A - no strep tag

<400> 25

Met Glu Thr Asp Thr Leu Leu Val Phe Val Leu Leu Val Trp Val Pro
1 5 10 15
Ala Gly Asn Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
20 25 30
Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
35 40 45
Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
50 55 60
Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
65 70 75 80
Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
85 90 95
Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
100 105 110
Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
115 120 125
Phe Gly Phe Gln Gly Arg Leu His Leu Ser Ala Gly Gln Arg Leu
130 135 140
Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
145 150 155 160

eolf-seql.txt

Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser
				165					170					175	
Gly	Asn	Gly	Ser	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val
			180					185					190		
Leu	Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala
		195					200					205			
Gly	Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu
	210					215					220				
Leu	Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu
225					230					235					240
Leu	Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala
				245					250					255	
Leu	His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala
			260					265					270		
Leu	Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala
		275					280					285			
Phe	Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu
	290					295					300				
Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu
305					310					315					320
Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser
				325					330					335	
Gly	Asn	Gly	Ser	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val
			340					345					350		
Leu	Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala
		355					360					365			
Gly	Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu
	370					375					380				
Leu	Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu
385					390					395					400
Leu	Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala
				405					410					415	
Leu	His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala
			420					425					430		
Leu	Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala
		435					440					445			
Phe	Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu
	450					455					460				
Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu
465					470					475					480
Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Ser	Ser
				485					490					495	
Ser	Ser	Ser	Ser	Ser	Gly	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro
			500					505					510		
Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro
		515					520					525			
Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr
	530					535					540				
Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn
545					550					555					560
Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg
				565					570					575	
Glu	Glu	Gln	Tyr	Ser	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val
			580					585					590		
Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser
		595					600					605			
Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys
	610					615					620				
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu
625					630					635					640
Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe
				645					650					655	
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu
			660					665					670		
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe
		675					680					685			
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly
	690					695					700				

eolf-seql.txt

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
 705 710 715 720
 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 725 730

<210> 26
 <211> 730
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD137L-wt fused to Seq_14

<400> 26
 Met Glu Thr Asp Thr Leu Leu Val Phe Val Leu Leu Val Trp Val Pro
 1 5 10 15
 Ala Gly Asn Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
 20 25 30
 Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
 35 40 45
 Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
 50 55 60
 Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
 65 70 75 80
 Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
 85 90 95
 Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
 100 105 110
 Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
 115 120 125
 Phe Gly Phe Gln Gly Arg Leu His Leu Ser Ala Gly Gln Arg Leu
 130 135 140
 Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
 145 150 155 160
 Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser
 165 170 175
 Gly Asn Gly Ser Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
 180 185 190
 Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
 195 200 205
 Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
 210 215 220
 Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
 225 230 235 240
 Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
 245 250 255
 Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
 260 265 270
 Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
 275 280 285
 Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu
 290 295 300
 Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
 305 310 315 320
 Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser
 325 330 335
 Gly Asn Gly Ser Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
 340 345 350
 Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
 355 360 365
 Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
 370 375 380
 Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
 385 390 395 400
 Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
 405 410 415
 Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala

eolf-seql.txt

```

Leu Thr Val 420 Leu Pro Pro Ala 425 Ser Ser Glu Ala Arg 430 Asn Ser Ala
435
Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu
450
Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
465
Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Ser Ser
485
Ser Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro
500
Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro
515
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
530
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
545
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
565
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Ser Val Leu Thr Val Leu
580
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
595
Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
610
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Ser Arg Glu Glu
625
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
645
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
660
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
675
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
690
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
705
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
725
730

```

<210> 27
 <211> 711
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD137L-wt fused to Seq_13 (no sig, no strep tag, no glyco)

```

<400> 27
Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
1 5 10 15
Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
20 25 30
Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
35 40 45
Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
50 55 60
Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
65 70 75 80
Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Thr Val Asp
85 90 95
Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
100 105 110
Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
115 120 125
His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
130 135 140

```

eofl-seql.txt

Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly	Ser
145					150					155					160
Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
				165					170					175	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			180					185					190		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		195					200					205			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	210					215					220				
Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln
225					230					235					240
Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp
				245					250					255	
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln
			260					265					270		
Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu
		275					280					285			
His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala
	290					295					300				
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly	Ser
305					310					315					320
Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
				325					330					335	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			340					345					350		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		355					360					365			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	370					375					380				
Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln
385					390					395					400
Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp
				405					410					415	
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln
			420					425					430		
Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu
		435					440					445			
His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala
	450					455					460				
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Ser	Ser	Ser	Ser	Ser	Ser
465					470					475					480
Ser	Gly	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro
				485					490					495	
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys
			500					505					510		
Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val
		515					520					525			
Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp
	530					535					540				
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr
545					550					555					560
Ser	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp
				565					570					575	
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu
			580					585					590		
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg
		595					600					605			
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys
	610					615					620				
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp
625					630					635					640
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys
				645					650					655	
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser
			660					665					670		
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser
		675					680					685			

eolf-seql.txt

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 690 695 700
 Leu Ser Leu Ser Pro Gly Lys
 705 710

<210> 28
 <211> 725
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD137L-wt fused to Seq_13 (no sig, no glyco)

<400> 28
 Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
 1 5 10 15
 Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
 20 25 30
 Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
 35 40 45
 Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
 50 55 60
 Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
 65 70 75 80
 Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Thr Val Asp
 85 90 95
 Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
 100 105 110
 Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
 115 120 125
 His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
 130 135 140
 Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly Ser
 145 150 155 160
 Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
 165 170 175
 Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
 180 185 190
 Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
 195 200 205
 Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
 210 215 220
 Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
 225 230 235 240
 Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr Val Asp
 245 250 255
 Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
 260 265 270
 Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
 275 280 285
 His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
 290 295 300
 Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly Ser
 305 310 315 320
 Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
 325 330 335
 Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
 340 345 350
 Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
 355 360 365
 Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
 370 375 380
 Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
 385 390 395 400
 Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr Val Asp
 405 410 415
 Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln

eolf-seql.txt

[illegible]

```
<210> 29
<211> 710
<212> PRT
<213> Artificial Sequence
```

<220>
<223> example

<400> 29

Gln 1	Gly	Met	Phe	Ala 5	Gln	Leu	Val	Ala	Gln 10	Asn	Val	Leu	Leu	Ile 15	Asp
Gly	Pro	Leu	Ser 20	Trp	Tyr	Ser	Asp	Pro 25	Gly	Leu	Ala	Gly	Val 30	Ser	Leu
Thr	Gly	Gly 35	Leu	Ser	Tyr	Lys	Glu 40	Asp	Thr	Lys	Glu	Leu 45	Val	Val	Ala
Lys	Ala 50	Gly	Val	Tyr	Tyr	Val 55	Phe	Phe	Gln	Leu	Glu 60	Leu	Arg	Arg	Val
Val 65	Ala	Gly	Glu	Gly	Ser 70	Gly	Ser	Val	Ser	Leu 75	Ala	Leu	His	Leu	Gln
Pro	Leu	Arg	Ser	Ala 85	Ala	Gly	Ala	Ala	Ala 90	Leu	Ala	Leu	Thr	Val 95	Asp
Leu	Pro	Pro	Ala 100	Ser	Ser	Glu	Ala	Arg 105	Asn	Ser	Ala	Phe	Gly 110	Phe	Gln
Gly	Arg	Leu 115	Leu	His	Leu	Ser	Ala 120	Gly	Gln	Arg	Leu	Gly 125	Val	His	Leu
His	Thr 130	Glu	Ala	Arg	Ala	Arg 135	His	Ala	Trp	Gln	Leu 140	Thr	Gln	Gly	Ala

eolf-seql.txt

Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly	Ser
145					150					155					160
Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
				165					170					175	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			180					185					190		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		195					200					205			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	210					215					220				
Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln
225					230					235					240
Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp
				245					250					255	
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln
			260					265					270		
Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu
		275					280					285			
His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala
	290					295					300				
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly	Ser
305					310					315					320
Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
				325					330					335	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			340					345					350		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		355					360					365			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	370					375					380				
Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln
385					390					395					400
Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp
				405					410					415	
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln
			420					425					430		
Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu
		435					440					445			
His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala
	450					455					460				
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Ser	Ser	Ser	Ser	Ser	Ser
465					470					475					480
Ser	Gly	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro
			485						490					495	
Pro	Val	Ala	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp
			500					505					510		
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp
		515					520					525			
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly
	530					535					540				
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn
545					550					555					560
Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp
				565					570					575	
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Gly	Leu	Pro
			580					585					590		
Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu
		595					600					605			
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn
	610					615					620				
Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile
625					630					635					640
Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr
				645					650					655	
Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys
			660					665					670		
Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gly	Asn	Val	Phe	Ser	Cys	
		675					680				685				

eolf-seql.txt

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 690 695 700
 Ser Leu Ser Pro Gly Lys
 705 710

<210> 30
 <211> 716
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> example

<400> 30
 Gln Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu
 1 5 10 15
 Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly
 20 25 30
 Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu
 35 40 45
 Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu
 50 55 60
 Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu
 65 70 75 80
 His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Leu Ala Leu
 85 90 95
 Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe
 100 105 110
 Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly
 115 120 125
 Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr
 130 135 140
 Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly
 145 150 155 160
 Asn Gly Ser Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln
 165 170 175
 Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly
 180 185 190
 Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr
 195 200 205
 Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln
 210 215 220
 Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser
 225 230 235 240
 Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala
 245 250 255
 Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn
 260 265 270
 Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln
 275 280 285
 Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp
 290 295 300
 Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser
 305 310 315 320
 Gly Ser Gly Asn Gly Ser Asp Leu Arg Gln Gly Met Phe Ala Gln Leu
 325 330 335
 Val Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser
 340 345 350
 Asp Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys
 355 360 365
 Glu Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val
 370 375 380
 Phe Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly
 385 390 395 400
 Ser Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly
 405 410 415
 Ala Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu

eolf-seql.txt

Ala	Arg	Asn	420	Ala	Phe	Gly	Phe	425	Gln	Gly	Arg	Leu	Leu	430	His	Leu	Ser
		435					440						445				
Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg		
	450				455						460						
His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg		
465				470					475						480		
Val	Gly	Ser	Ser	Ser	Gly	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro			
			485					490					495				
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe		
			500					505					510				
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val		
		515					520					525					
Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe		
	530					535					540						
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro		
545					550					555					560		
Arg	Glu	Glu	Gln	Tyr	Ser	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr		
				565					570					575			
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val		
			580					585					590				
Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala		
		595					600					605					
Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg		
	610					615					620						
Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly		
625					630					635					640		
Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro		
				645					650					655			
Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser		
			660					665					670				
Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln		
		675					680					685					
Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His		
	690					695				700							
Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys						
705					710					715							

<210> 31

<211> 720

<212> PRT

<213> Artificial Sequence

<220>

<223> example

<400> 31

Gln	Leu	Arg	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu		
1			5					10					15				
Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly		
		20					25					30					
Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu		
		35				40					45						
Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu		
	50				55					60							
Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu		
65				70				75					80				
His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu		
			85					90				95					
Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe		
		100					105					110					
Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly		
		115				120					125						
Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr		
	130					135				140							
Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly		
145					150					155					160		

eolf-seql.txt

Asn	Gly	Ser	Asp	Leu	Arg	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln
				165					170					175	
Asn	Val	Leu	Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly
			180					185					190		
Leu	Ala	Gly	Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr
		195					200					205			
Lys	Glu	Leu	Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln
	210					215					220				
Leu	Glu	Leu	Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser
225					230					235					240
Leu	Ala	Leu	His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala
				245					250					255	
Leu	Ala	Leu	Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn
			260					265					270		
Ser	Ala	Phe	Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln
		275					280					285			
Arg	Leu	Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp
	290					295					300				
Gln	Leu	Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser
305					310					315					320
Gly	Ser	Gly	Asn	Gly	Ser	Asp	Leu	Arg	Gln	Gly	Met	Phe	Ala	Gln	Leu
				325					330					335	
Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser
			340					345					350		
Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys
		355					360					365			
Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val
	370					375					380				
Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly
385					390					395					400
Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly
				405					410					415	
Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu
			420					425					430		
Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser
		435					440					445			
Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg
	450					455					460				
His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg
465					470					475					480
Val	Gly	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Gly	Ser	Cys	Asp	Lys	Thr
				485					490					495	
His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser
			500					505					510		
Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg
		515					520					525			
Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro
	530					535					540				
Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala
545					550					555					560
Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Ser	Ser	Thr	Tyr	Arg	Val	Val
				565					570					575	
Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr
			580					585					590		
Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr
		595					600					605			
Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu
	610					615					620				
Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys
625					630					635					640
Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser
				645					650					655	
Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp
			660					665					670		
Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser
		675					680					685			
Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala
	690					695					700				

eolf-seql.txt

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 705 710 715 720

<210> 32
 <211> 711
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> example

<400> 32
 Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile
 1 5 10 15
 Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser
 20 25 30
 Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val
 35 40 45
 Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg
 50 55 60
 Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu
 65 70 75 80
 Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Leu Ala Leu Thr Val
 85 90 95
 Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe
 100 105 110
 Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His
 115 120 125
 Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly
 130 135 140
 Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly
 145 150 155 160
 Ser Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu
 165 170 175
 Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val
 180 185 190
 Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val
 195 200 205
 Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg
 210 215 220
 Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His
 225 230 235 240
 Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr
 245 250 255
 Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly
 260 265 270
 Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val
 275 280 285
 His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln
 290 295 300
 Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn
 305 310 315 320
 Gly Ser Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu
 325 330 335
 Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly
 340 345 350
 Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu
 355 360 365
 Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu
 370 375 380
 Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu
 385 390 395 400
 His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu
 405 410 415
 Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe

eofl-seql.txt

Gly	Phe	Gln	420	Arg	Leu	Leu	His	425	Leu	Ser	Ala	Gly	Gln	430	Arg	Leu	Gly	
Val	His	Leu	435	His	Thr	Glu	Ala	440	Arg	Ala	Arg	His	Ala	445	Trp	Gln	Leu	Thr
Gln	Gly	Ala	450	Thr	Val	Leu	Gly	455	Leu	Phe	Arg	Val	Gly	460	Ser	Ser	Ser	Ser
465	Ser	Gly	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	475	Pro	Pro	Cys	Pro	Ala	Pro	480
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Pro	Lys	495
Asp	Thr	Leu	500	Met	Ile	Ser	Arg	Thr	505	Pro	Glu	Val	Thr	Cys	Val	Val	Val	510
Asp	Val	Ser	515	His	Glu	Asp	Pro	520	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	525
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Val	Asp	540
545	Ser	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	560	555
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	570	Lys	Val	Ser	Asn	Lys	Ala	Leu	575	585
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	590	600	605
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	610	620	625
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	630	635	640
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	645	650	655
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	660	665	670
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	675	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	680	685
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	690	700	705
Leu	Ser	Leu	Ser	Pro	Gly	Lys	710											

<210> 33

<211> 714

<212> PRT

<213> Artificial Sequence

<220>

<223> example

<400> 33

Gln	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile			
1	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser		
	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val		
	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg		
	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu		
65	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Leu	Ala	Leu	Thr	Val			
	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe		
	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His		
	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly		
145	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly		

eolf-seql.txt

Ser	Gly	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu
				165					170					175	
Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val
			180					185					190		
Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val
		195					200					205			
Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg
	210					215					220				
Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His
225					230					235					240
Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr
				245					250					255	
Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly
			260					265					270		
Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val
		275					280					285			
His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln
	290					295					300				
Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn
305					310					315					320
Gly	Ser	Gly	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu
				325					330					335	
Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly
			340					345					350		
Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu
		355					360					365			
Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu
	370					375					380				
Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu
385					390					395					400
His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu
				405					410					415	
Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe
			420					425					430		
Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly
		435					440					445			
Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr
	450					455					460				
Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Ser	Ser	Ser
465					470					475					480
Ser	Ser	Ser	Ser	Gly	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys
				485					490					495	
Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro
			500					505					510		
Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys
		515					520					525			
Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp
	530					535					540				
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu
545					550					555					560
Glu	Gln	Tyr	Ser	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu
				565					570					575	
His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn
			580					585					590		
Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly
		595					600					605			
Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu
	610					615					620				
Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr
625					630					635					640
Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn
				645					650					655	
Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe
			660					665					670		
Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn
		675					680					685			
Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr
	690					695					700				

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
705 710

<210> 34
<211> 714
<212> PRT
<213> Artificial Sequence

<220>
<223> example

<400> 34
Ser Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile
1 5 10 15
Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser
20 25 30
Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val
35 40 45
Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg
50 55 60
Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu
65 70 75 80
Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Leu Ala Leu Thr Val
85 90 95
Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe
100 105 110
Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His
115 120 125
Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly
130 135 140
Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly
145 150 155 160
Ser Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu
165 170 175
Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val
180 185 190
Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val
195 200 205
Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg
210 215 220
Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His
225 230 235 240
Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Leu Ala Leu Thr
245 250 255
Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly
260 265 270
Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val
275 280 285
His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln
290 295 300
Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn
305 310 315 320
Gly Ser Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu
325 330 335
Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly
340 345 350
Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu
355 360 365
Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu
370 375 380
Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu
385 390 395 400
His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu
405 410 415
Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe
420 425 430
Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly

eolf-seql.txt

```

      435      440      445
Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr
  450      455      460
Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Ser Ser Ser
  465      470      475      480
Ser Ser Ser Ser Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
      485      490      495
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
      500      505      510
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
      515      520      525
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
      530      535      540
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
  545      550      555      560
Glu Gln Tyr Ser Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
      565      570      575
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
      580      585      590
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
      595      600      605
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
      610      615      620
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
  625      630      635      640
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
      645      650      655
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
      660      665      670
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
      675      680      685
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
      690      695      700
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
  705      710

```

<210> 35
 <211> 711
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> FAKE SEQ --> PLEASE REPLACE BY CORRECT SEQ

```

<400> 35
Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
  1      5      10      15
Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
      20      25      30
Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
      35      40      45
Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
      50      55      60
Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
  65      70      75      80
Pro Leu Arg Ser Ala Asn Gly Ser Ala Ala Leu Ala Leu Thr Val Asp
      85      90      95
Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
      100      105      110
Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
      115      120      125
His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
      130      135      140
Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly Ser
  145      150      155      160
Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
      165      170      175

```

eolf-seql.txt

Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
Thr	Gly	Gly	180	Ser	Tyr	Lys	Glu	185	Asp	Thr	Lys	Glu	190	Val	Ala
Lys	Ala	Gly	195	Val	Tyr	Tyr	Val	200	Phe	Gln	Leu	Glu	205	Leu	Arg
Val	Ala	Gly	210	Glu	Gly	Ser	Gly	215	Ser	Val	Ser	Leu	220	Ala	Leu
225	Pro	Leu	Arg	Ser	Ala	Asn	Gly	Ser	Ala	Ala	Leu	Ala	235	Leu	Thr
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	250	Gly	Phe
Gly	Arg	Leu	260	His	Leu	Ser	Ala	265	Gly	Gln	Arg	Leu	270	Val	His
His	Thr	Glu	275	Ala	Arg	Ala	Arg	280	His	Ala	Trp	Gln	285	Leu	Thr
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	295	Gly	Ser	Gly	Ser	300	Gly	Asn
305	Gln	Gly	Met	Phe	Ala	Gln	Leu	310	Val	Ala	Gln	Asn	315	Val	Leu
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	325	Pro	Gly	Leu	Ala	330	Gly	Val
Thr	Gly	Gly	340	Leu	Ser	Tyr	Lys	345	Asp	Thr	Lys	Glu	350	Leu	Val
Lys	Ala	Gly	355	Val	Tyr	Tyr	Val	360	Phe	Gln	Leu	Glu	365	Leu	Arg
Val	Ala	Gly	370	Glu	Gly	Ser	Gly	375	Ser	Val	Ser	Leu	380	Ala	Leu
385	Pro	Leu	Arg	Ser	Ala	Asn	Gly	390	Ser	Ala	Ala	Leu	395	Ala	Leu
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	405	Arg	Asn	Ser	Ala	410	Phe	Gly
Gly	Arg	Leu	420	Leu	His	Leu	Ser	425	Ala	Gly	Gln	Arg	430	Leu	Gly
His	Thr	Glu	435	Ala	Arg	Ala	Arg	440	His	Ala	Trp	Gln	445	Leu	Thr
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	455	Gly	Ser	Ser	Ser	460	Ser	Ser
465	Ser	Gly	Ser	Cys	Asp	Lys	Thr	470	His	Thr	Cys	Pro	475	Pro	Pro
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	485	Phe	Leu	Phe	Pro	490	Pro	Cys
Asp	Thr	Leu	500	Met	Ile	Ser	Arg	505	Pro	Glu	Val	Thr	510	Cys	Val
Asp	Val	Ser	515	His	Glu	Asp	Pro	520	Glu	Val	Lys	Phe	525	Trp	Tyr
Gly	Val	Glu	530	Val	His	Asn	Ala	535	Lys	Thr	Lys	Pro	540	Arg	Glu
545	Ser	Ser	Thr	Tyr	Arg	Val	Val	550	Ser	Val	Leu	Thr	555	Val	Leu
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	565	Cys	Lys	Val	Ser	570	Asn	Lys
Pro	Ala	Pro	580	Ile	Glu	Lys	Thr	585	Ile	Ser	Lys	Ala	590	Gly	Gln
Glu	Pro	Gln	595	Val	Tyr	Thr	Leu	600	Pro	Pro	Ser	Arg	605	Glu	Met
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	615	Val	Lys	Gly	Phe	620	Tyr	Pro
625	Ile	Ala	Val	Glu	Trp	Glu	Ser	630	Asn	Gly	Gln	Pro	635	Glu	Asn
Thr	Thr	Pro	645	Val	Leu	Asp	Ser	650	Asp	Gly	Ser	Phe	655	Phe	Leu
Lys	Leu	Thr	660	Val	Asp	Lys	Ser	665	Trp	Gln	Gln	Gly	670	Asn	Val
Cys	Ser	Val	675	Met	His	Glu	Ala	680	Leu	His	Asn	His	685	Thr	Gln
Leu	Ser	Leu	Ser	Pro	Gly	Lys		695					700		
705															

eolf-seql.txt

<210> 36
 <211> 472
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> example of scCD137L-RBD module

<400> 36
 Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
 1 5 10 15
 Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
 20 25 30
 Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
 35 40 45
 Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
 50 55 60
 Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
 65 70 75 80
 Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr Val Asp
 85 90 95
 Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
 100 105 110
 Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
 115 120 125
 His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
 130 135 140
 Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly Ser
 145 150 155 160
 Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
 165 170 175
 Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
 180 185 190
 Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
 195 200 205
 Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
 210 215 220
 Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
 225 230 235 240
 Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr Val Asp
 245 250 255
 Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
 260 265 270
 Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
 275 280 285
 His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
 290 295 300
 Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly Ser
 305 310 315 320
 Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp
 325 330 335
 Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu
 340 345 350
 Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala
 355 360 365
 Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val
 370 375 380
 Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
 385 390 395 400
 Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr Val Asp
 405 410 415
 Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
 420 425 430
 Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
 435 440 445
 His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala

450
Thr Val Leu Gly Leu Phe Arg Val
465 470

460

<210> 37
<211> 2240
<212> DNA
<213> Artificial Sequence

<220>
<223> DNA sequence encoding SEQ ID NO:25

<400> 37
aagctttagg gataacaggg taatagccgc caccatggag actgacaccc tgctggtggt 60
cgtgctgctg gtctgggtgc ctgcaggaaa tggacagggc atgttcgctc aactgggtcgc 120
acagaacgtg ctgctcattg acggtcccct gtcttggtac tccgatccag ggttggcagg 180
agtgtccttg acaggagggc tgtcctataa ggaggatacc aaagagctgg tggtagcaaa 240
ggctgggtgtg tattacgtgt tctttcagct ggagctgcgc agagtcgtcg caggcgaagg 300
atctggtagt gtgtcactgg cactgcactt gcagcccctt cgggtccgctg ccggggcagc 360
agcactggcc ctgaccgtcg atctgccacc cgcttctagc gaggcacgaa actcagcctt 420
tgggtttcag ggtcgcctgc tgcacctgag cgccggacag aggctgggag ttcattctgca 480
caccgaggcc agagccagac acgcttggca gttgactcag ggagctacgg tcctcggctc 540
gtttcgagta ggcagcggaa gcggaatgg ctctcagggc atgtttgctc agctggtagc 600
ccagaacgta ctctgatcg atggccctct ttcattgtac tcagaccccg gactggccgg 660
agttagcctt acagggtggc ttagttataa ggaggacaca aaggaattgg ttgtggccaa 720
agctggcgtg tactatgtgt tcttccagct tgagctccgc agagtcgtgg ctggggaggg 780
ctctggcagt gtgagccttg cccttcatct gcaacctttg cggagcgcag ccggcgctgc 840
tgactggcc cttacagtgg atttgccacc cgcaagtagt gaagctcgca attccgcatt 900
cggtttccag ggccgtctgc tccatctttc tgccgggtcaa cgtctgggag ttcacctcca 960
cactgaggct agggccaggc atgcttggca gctgactcaa ggagccactg tcttgggact 1020
ctttcgggta ggctccgggt ctggcaacgg ctcccagggg atgtttgccc aactgggtcgc 1080
ccagaatgtc ctgctcatcg atggtcctct gagctggtat tccgaccctg gactgggtgg 1140
tgtgagcctg actggcggac tctcctacaa agaggacacc aaggaactgg tggtaggcaaa 1200
agccgggggtg tactacgtgt tcttccagtt ggaactgcgg cgggttggtg ctggcgaggg 1260
atcaggttcc gttagtctgg ccctgcacct ccagcctctg aggtctgctg ctggtgccgc 1320
cgctctggcc ttgaccgtcg acctcccacc cgcattcttc gaagcccga attcagcctt 1380
cgggttccag ggcagactgc tgcattctgag tgctggacag cgccttgggg ttcattctcca 1440
caccgaagcc agggcccagc atgcctggca gctcacacaa ggcgcaaccg ttttggggct 1500
ctttcgtgtg ggatcctcga gttcatcgtc ctcatccggc tcatgtgata agaccacac 1560
ctgccctccc tgtcctgccc ctgagctgct gggcggacct tctgtgttcc tgttcccccc 1620

eolf-seql.txt

```

caagcctaag gacaccctga tgatctccag gaccctgag gtgacctgtg tgggtggtgga 1680
cgtgtctcac gaagatcccg aggtgaagtt caactggtac gtggacggcg tggaggtcca 1740
caacgccaag accaagccta gggaggagca gtacagctcc acctaccggg tgggtgtctgt 1800
gctgaccgtg ctgcaccagg attggctgaa cggaaggag tataagtgtg aggtctccaa 1860
caaggccctg cctgccccca tcgagaaaac catctccaag gccaagggcc agcctcgga 1920
gcctcaggtg tacaccctgc ctcttagcag ggaggagatg accaagaacc aggtgtccct 1980
gacctgtctg gtgaagggt tctacccttc cgatatcgcc gtggagtggg agtctaattg 2040
ccagcccag aacaactaca agaccacccc tcctgtgctg gactctgacg gtccttctt 2100
cctgtactcc aagctgaccg tggacaagtc cagatggcag cagggcaacg tgttctcctg 2160
ctccgtgatg cagcaggccc tgcacaatca ctacaccag aagtcctgt ctctgagtc 2220
gggcaagtaa taggcgcgcc 2240

```

<210> 38
 <211> 229
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> homotrimeric CD137L fused to RB69 FOLDON

```

<400> 38
Met Glu Thr Asp Thr Leu Leu Val Phe Val Leu Leu Val Trp Val Pro
1      5      10      15
Ala Gly Asn Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val
20     25     30
Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala
35     40     45
Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu
50     55     60
Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu
65     70     75     80
Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala
85     90     95
Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala
100    105    110
Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala
115    120    125
Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu
130    135    140
Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu
145    150    155    160
Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser
165    170    175
Ser Gly Ser Ser Gly Ser Ser Gly Ser Gly Tyr Ile Glu Asp Ala Pro
180    185    190
Ser Asp Gly Lys Phe Tyr Val Arg Lys Asp Gly Ala Trp Val Glu Leu
195    200    205
Pro Thr Ala Ser Gly Pro Ser Ser Ser Ser Ser Ala Trp Ser His
210    215    220
Pro Gln Phe Glu Lys
225

```

<210> 39
 <211> 481
 <212> PRT
 <213> Artificial Sequence

eolf-seql.txt

<220>

<223> single chain CD137 lignad RBD (example)

<400> 39

Gln	Leu	Arg	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu
1				5					10					15	
Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly
			20					25					30		
Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu
		35				40					45				
Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu
	50					55				60					
Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu
65				70					75					80	
His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu
			85						90					95	
Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe
			100					105					110		
Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly
		115					120					125			
Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr
	130					135				140					
Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly
145					150					155					160
Asn	Gly	Ser	Asp	Leu	Arg	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln
			165						170					175	
Asn	Val	Leu	Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly
		180						185					190		
Leu	Ala	Gly	Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr
		195					200					205			
Lys	Glu	Leu	Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln
	210					215					220				
Leu	Glu	Leu	Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser
225					230					235					240
Leu	Ala	Leu	His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala
			245						250					255	
Leu	Ala	Leu	Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn
		260						265					270		
Ser	Ala	Phe	Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln
		275					280					285			
Arg	Leu	Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp
	290					295					300				
Gln	Leu	Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser
305					310					315					320
Gly	Ser	Gly	Asn	Gly	Ser	Asp	Leu	Arg	Gln	Gly	Met	Phe	Ala	Gln	Leu
			325						330					335	
Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser
			340					345					350		
Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys
		355					360					365			
Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val
	370					375					380				
Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly
385					390					395					400
Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly
			405						410					415	
Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu
			420					425					430		
Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser
		435					440					445			
Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg
	450					455					460				
His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg
465					470					475					480
Val															

eolf-seql.txt

<210> 40
 <211> 475
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> single chain CD137 ligand RBD (example)

<400> 40
 Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile
 1 5 10 15
 Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser
 20 25 30
 Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val
 35 40 45
 Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg
 50 55 60
 Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu
 65 70 75 80
 Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr Val
 85 90 95
 Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe
 100 105 110
 Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His
 115 120 125
 Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly
 130 135 140
 Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly
 145 150 155 160
 Ser Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu
 165 170 175
 Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val
 180 185 190
 Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val
 195 200 205
 Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg
 210 215 220
 Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His
 225 230 235 240
 Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr
 245 250 255
 Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly
 260 265 270
 Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val
 275 280 285
 His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln
 290 295 300
 Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn
 305 310 315 320
 Gly Ser Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu
 325 330 335
 Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly
 340 345 350
 Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu
 355 360 365
 Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu
 370 375 380
 Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu
 385 390 395 400
 His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu
 405 410 415
 Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe
 420 425 430
 Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly
 435 440 445
 Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr

eolf-seql.txt

450 455 460
Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val
465 470 475

<210> 41
<211> 475
<212> PRT
<213> Artificial Sequence

<220>
<223> single chain CD137 ligand RBD (example)

<400> 41
Gln Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu Ile
1 5 10 15
Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser
20 25 30
Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val Val
35 40 45
Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg
50 55 60
Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu
65 70 75 80
Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Leu Ala Leu Thr Val
85 90 95
Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe
100 105 110
Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His
115 120 125
Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly
130 135 140
Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn Gly
145 150 155 160
Ser Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu
165 170 175
Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val
180 185 190
Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val
195 200 205
Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg
210 215 220
Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His
225 230 235 240
Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr
245 250 255
Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly
260 265 270
Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val
275 280 285
His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln
290 295 300
Gly Ala Thr Val Leu Gly Leu Phe Arg Val Gly Ser Gly Ser Gly Asn
305 310 315 320
Gly Ser Gly Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu
325 330 335
Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly
340 345 350
Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu
355 360 365
Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu
370 375 380
Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu
385 390 395 400
His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu
405 410 415
Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe
420 425 430

eolf-seql.txt

Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly
		435					440					445			
Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr
	450					455					460				
Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val					
465					470					475					

<210> 42
 <211> 475
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> single chain CD137 lignad RBD (example)

<400> 42															
Ser	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile
1			5						10					15	
Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser
			20					25					30		
Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val
		35					40					45			
Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg
	50					55					60				
Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu
65					70					75					80
Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr	Val
			85					90						95	
Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe
			100					105					110		
Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His
		115					120					125			
Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly
	130					135					140				
Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly
145					150					155					160
Ser	Gly	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu
			165						170					175	
Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val
			180					185					190		
Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val
		195					200					205			
Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg
	210					215					220				
Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His
225					230					235					240
Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu	Thr
			245						250					255	
Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly
			260					265					270		
Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val
		275					280					285			
His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln
	290					295					300				
Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn
305					310					315					320
Gly	Ser	Gly	Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu
			325						330					335	
Leu	Ile	Asp	Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly
			340					345					350		
Val	Ser	Leu	Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu
		355					360					365			
Val	Val	Ala	Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu
	370					375					380				
Arg	Arg	Val	Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu
385					390					395					400
His	Leu	Gln	Pro	Leu	Arg	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Leu	Ala	Leu

eolf-seql.txt

			405					410				415			
Thr	Val	Asp	Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe
			420					425				430			
Gly	Phe	Gln	Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly
		435					440					445			
Val	His	Leu	His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr
	450					455					460				
Gln	Gly	Ala	Thr	Val	Leu	Gly	Leu	Phe	Arg	Val					
465					470					475					

<210> 43

<211> 472

<212> PRT

<213> Artificial Sequence

<220>

<223> single chain CD137 ligand RBD (example)

<400> 43

Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
1				5				10						15	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			20					25					30		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		35					40					45			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	50					55					60				
Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln
65					70					75					80
Pro	Leu	Arg	Ser	Ala	Asn	Gly	Ser	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp
				85					90					95	
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln
			100					105					110		
Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu
		115					120					125			
His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala
	130					135					140				
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly	Ser
145					150					155					160
Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
				165					170					175	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			180					185					190		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		195					200					205			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	210					215					220				
Val	Ala	Gly	Glu	Gly	Ser	Gly	Ser	Val	Ser	Leu	Ala	Leu	His	Leu	Gln
225					230					235					240
Pro	Leu	Arg	Ser	Ala	Asn	Gly	Ser	Ala	Ala	Leu	Ala	Leu	Thr	Val	Asp
				245					250					255	
Leu	Pro	Pro	Ala	Ser	Ser	Glu	Ala	Arg	Asn	Ser	Ala	Phe	Gly	Phe	Gln
			260					265					270		
Gly	Arg	Leu	Leu	His	Leu	Ser	Ala	Gly	Gln	Arg	Leu	Gly	Val	His	Leu
		275					280					285			
His	Thr	Glu	Ala	Arg	Ala	Arg	His	Ala	Trp	Gln	Leu	Thr	Gln	Gly	Ala
	290					295					300				
Thr	Val	Leu	Gly	Leu	Phe	Arg	Val	Gly	Ser	Gly	Ser	Gly	Asn	Gly	Ser
305					310					315					320
Gln	Gly	Met	Phe	Ala	Gln	Leu	Val	Ala	Gln	Asn	Val	Leu	Leu	Ile	Asp
				325					330					335	
Gly	Pro	Leu	Ser	Trp	Tyr	Ser	Asp	Pro	Gly	Leu	Ala	Gly	Val	Ser	Leu
			340					345					350		
Thr	Gly	Gly	Leu	Ser	Tyr	Lys	Glu	Asp	Thr	Lys	Glu	Leu	Val	Val	Ala
		355					360					365			
Lys	Ala	Gly	Val	Tyr	Tyr	Val	Phe	Phe	Gln	Leu	Glu	Leu	Arg	Arg	Val
	370					375					380				


```

                                eof-seql.txt
Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln
385                                     390                                     400
Pro Leu Arg Ser Ala Asn Gly Ser Ala Ala Leu Ala Leu Thr Val Asp
                                     405                                     410                                     415
Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln
                                     420                                     425                                     430
Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu
                                     435                                     440                                     445
His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala
450                                     455                                     460
Thr Val Leu Gly Leu Phe Arg Val
465                                     470

```